Lipid-modified nucleic acid compounds and methods

The introduction of double-stranded oligonucleotide compounds through lipid modification into cells under free uptake conditions has solved the problem of low nucleic acid delivery efficiency in the prior art and achieved effective regulation of PTEN mRNA.

CN113166191BActive Publication Date: 2024-12-03NOVARTIS AG
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN201980050809.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-01-17
Filing Date
2019-05-30
Publication Date
2024-12-03
Estimated Expiration
2039-05-30

AI Technical Summary

Technical Problem

The prior art is difficult to effectively deliver therapeutic nucleic acids to cells and lacks efficient delivery strategies.

Method used

Lipid-modified double-stranded oligonucleotide compounds are provided to contact cells with these compounds by free uptake conditions to achieve their introduction to cells.

Benefits of technology

It improves the delivery efficiency and expression regulation ability of nucleic acid compounds in cells, significantly reduces the expression level of PTEN mRNA, and demonstrates the effectiveness of lipid-modified compounds in cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113166191B_ABST
    Figure CN113166191B_ABST
Patent Text Reader

Abstract

In particular, the present invention discloses a lipid-modified nucleic acid compound having the following structure (I), its preparation and use. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 678,013, filed May 30, 2018, and U.S. Provisional Patent Application No. 62 / 793,597, filed January 17, 2019, which are incorporated herein in their entirety and for all purposes.

[0003] Reference to a "Sequence Listing", table or computer program listing appendix submitted as an ASCII file

[0004] The Sequence Listing written into file 052974-502001WO_ST25.TXT (created on May 23, 2019, 3,449 bytes, machine format IBM-PC, MS Windows operating system) is hereby incorporated by reference. background Technical Field

[0006] The present disclosure relates to the field of biologically active nucleic acid compounds. More specifically, the present disclosure relates to lipid-modified nucleic acid compounds, their preparation, and uses thereof. Background Art

[0008] The delivery of therapeutic nucleic acids into cells remains a challenging area of ​​research. Thus, there is a need for improved nucleic acid compounds and strategies for introducing such compounds into cells. Summary of the Invention

[0009] Specifically provided herein are compounds or lipid-modified nucleic acid compounds having the following structures:

[0010]

[0011] A is an oligonucleotide, a nucleic acid, a polynucleotide, a nucleotide or an analog thereof, or a nucleoside or an analog thereof. In embodiments, A is an oligonucleotide. In embodiments, A is a nucleic acid. In embodiments, A is a polynucleotide. In embodiments, A is a nucleotide or an analog thereof. In embodiments, A is a nucleoside or an analog thereof.

[0012] L 3 and L 4 and -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO-O-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0013] L5 Yes-L 5A -L 5B -L 5C -L 5D -L 5E -, and L 6 Yes-L 6A -L 6B -L 6C -L 6D -L 6E -.L 5A 、L 5B 、L 5C 、L 5D 、L 5E 、L 6A 、L 6B 、L 6C 、L 6D and L 6E and -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0014] R 1 and R 2 are independently unsubstituted C1-C 25 Alkyl, where R 1 and R 2 At least one of them is unsubstituted C9-C 19 alkyl; and R 3 is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0015] t is an integer from 1 to 5.

[0016] In an embodiment, provided herein are lipid-conjugated compounds having the structure of Formula I:

[0017]

[0018] or a pharmaceutically acceptable salt thereof, wherein: A, X1 and m have any value described herein.

[0019] In an embodiment, provided herein are lipid-conjugated compounds having the structure of Formula II:

[0020]

[0021] or a pharmaceutically acceptable salt thereof, wherein A has any value described herein.

[0022] In an embodiment, provided herein are lipid-conjugated compounds having the structure of Formula III:

[0023]

[0024] or a pharmaceutically acceptable salt thereof, wherein: A, Z1 and Z2 have any value described herein.

[0025] In an embodiment, provided herein is a cell containing a compound as disclosed and described herein.

[0026] In an embodiment, provided herein is a method for introducing a modified double-stranded oligonucleotide into a cell in vitro, comprising contacting the cell with a compound as disclosed and described herein under uptake-free conditions.

[0027] In an embodiment, provided herein is a method for introducing a modified double-stranded oligonucleotide ex vivo comprising contacting a cell with a compound as disclosed and described herein under uptake-free conditions. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The structure of the synthetic DHA-conjugated siRNA is shown.

[0029] Figure 2 The structure of the synthesized DTx-01-08 conjugated siRNA is shown.

[0030] Figure 3 Shown is the structure of a synthetic PTEN siRNA with C10 to C22 saturated fatty acids attached.

[0031] Figure 4 The structure of the synthetic C16 LCFA-conjugated siRNA is shown.

[0032] Figure 5 Shown are the structures of synthetic PTEN siRNA conjugated with LCFA at the 3' and 5' positions.

[0033] Figure 6 Shown is the structure of a synthetic PTEN siRNA with a conjugated C16LCFA containing a terminal COOH group.

[0034] Figure 7The structures of the synthesized DTx-01-08 conjugated DTxO-0038, DTxO-0033, and DTXO-0034 siRNAs are shown.

[0035] Figure 8 Shown is the structure of DTxO-0003 siRNA conjugated to a motif with one or more unsaturated LCFAs.

[0036] Figure 9 Shown is the structure of DTxO-0003 siRNA conjugated to a motif with a rigid linker.

[0037] Figure 10 Shown is the structure of DTxO-0003 siRNA conjugated to a motif with three LCFAs.

[0038] Figure 11 Shown are the structures of DTxO-0003 siRNA or DTxO-0038 siRNA conjugated to the DTx-01-08 motif at the 5′ end of the passenger strand or the 3′ end of the guide strand.

[0039] Figure 12A Shown are the structures of DTxO-0003 siRNA conjugated to the DTx-01-50, DTx-01-51, DTx-01-52, DTx-01-53, DTx-01-54, or DTx-01-55 motifs.

[0040] Figure 12B Shown are the structures of DTxO-0003 siRNA conjugated to the DTx-03-50, DTx-03-51, DTx-03-52, DTx-03-53, DTx-03-54, or DTx-03-55 motifs.

[0041] Figure 12C Shown are the structures of DTxO-0003 siRNA conjugated to the DTx-06-50, DTx-06-51, DTx-06-52, DTx-06-53, DTx-06-54, or DTx-06-55 motifs.

[0042] Figure 13 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells 48 hours after transfection with various concentrations of compounds 2, 7, 8, 26, and 1.

[0043] Figure 14 Shown are the percentages of PTEN mRNA expression in HEK293 cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 7, 8, 26 and 1 for 48 hours under free uptake conditions.

[0044] Figure 15 Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 7, 8, 26 and 1 for 48 hours under free uptake conditions.

[0045] Figure 16 Shown is a comparison of the effects of conjugates including a rigid linker structure or conjugates including three LCFAs on PTEN mRNA expression 48 hours after transfection of the compounds into HEK293 cells.

[0046] Figure 17 Shown is a comparison of the effects of a conjugate comprising a rigid linker structure or a conjugate comprising three LCFAs on PTEN mRNA expression in HUVEC cells after 48 hours of free uptake of the compounds.

[0047] Figure 18 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells 48 hours after transfection with various concentrations of compounds 2, 9, and 1.

[0048] Figure 19 Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 9, and 1 for 48 hours under free uptake conditions.

[0049] Figure 20 Shown are the effects of compounds having a conjugate moiety attached to the 5' end or the 3' end of the passenger strand of two different siRNAs 48 hours after transfection into HEK293 cells.

[0050] Figure 21 Shown are the effects of compounds having a conjugate moiety attached to the 5' end or the 3' end of the passenger strand of two different siRNAs after 48 hours of free uptake into HUVEC cells.

[0051] Figure 22 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells 48 hours after transfection with various concentrations of compounds 2, 25, 24, and 1.

[0052] Figure 23 Shown are the percentages of PTEN mRNA expression relative to PBS control in NIH3T3 cells 48 hours after transfection with various concentrations of compounds 2, 25, 24, and 1.

[0053] Figure 24Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 25, 24 and 1 for 48 hours under free uptake conditions.

[0054] Figure 25 Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 25, 24 and 1 for 96 hours under free uptake conditions.

[0055] Figure 26 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells after exposure of cells to various concentrations of compounds 2, 25, 24 and 1 for 48 hours under free uptake conditions.

[0056] Figure 27 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells after exposure of cells to various concentrations of compounds 2, 25, 24 and 1 for 96 hours under free uptake conditions.

[0057] Figure 28 Shown are the percentages of PTEN mRNA expression in NIH3T3 cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 25, 24 and 1 for 48 hours under free uptake conditions.

[0058] Figure 29 Shown are the percentages of PTEN mRNA expression relative to PBS control in NIH3T3 cells after exposure of cells to various concentrations of compounds 2, 25, 24, and 1 for 96 hours under free uptake conditions.

[0059] Figure 30 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells 48 hours after transfection with various concentrations of compounds 2, 20, 21 and 23.

[0060] Figure 31 Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 1, 2, 20, 21 and 23 for 48 hours under free uptake conditions.

[0061] Figure 32 Shown is a comparison of the effects of conjugates containing saturated or unsaturated fatty acids on PTEN mRNA expression following transfection into HEK293 cells.

[0062] Figure 33 Shown is a comparison of the effects of conjugates containing saturated or unsaturated fatty acids on PTEN mRNA expression following free uptake into HUVEC cells.

[0063] Figure 34 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells 48 hours after transfection with various concentrations of compounds 2, 10, 11, 12, and 1.

[0064] Figure 35 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells 48 hours after transfection with various concentrations of compounds 2, 13, 14, 15, and 1.

[0065] Figure 36 Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 10, 11, 12, and 1 for 48 hours under free uptake conditions.

[0066] Figure 37 Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 13, 14, 15, and 1 for 48 hours under free uptake conditions.

[0067] Figure 38 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells 48 hours after transfection with various concentrations of compounds 2, 16, 17, 18, and 1.

[0068] Figure 39 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells after exposure of cells to various concentrations of compounds 2, 16, 17, 18 and 1 for 48 hours under free uptake conditions.

[0069] Figure 40 Shown are the percentages of PTEN mRNA expression relative to PBS control in differentiated SH-SY5Y cells after exposure of cells to various concentrations of compounds 2, 16, 17, 18, and 1 for 48 hours under free uptake conditions.

[0070] Figure 41 Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 16, 17, 18, and 1 for 48 hours under free uptake conditions.

[0071] Figure 42 Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 16, 17, 18, and 1 for 96 hours under free uptake conditions.

[0072] Figure 43 Shown are the percentages of PTEN mRNA expression in primary rat neurons relative to PBS control after exposure of cells to various concentrations of compounds 2, 16, 17, 18, and 1 for 96 hours under free uptake conditions.

[0073] Figure 44 Shown are the percentages of PTEN mRNA expression in primary rat neurons relative to PBS control after exposure of cells to various concentrations of compounds 2, 16, 17, 18, and 1 for 7 days under free uptake conditions.

[0074] Figure 45A Shown are the percentages of VEGFR1 expression in HUVEC cells relative to PBS control 48 hours after transfection with various concentrations of compounds 3 and 1.

[0075] Figure 45B Shown are the percentages of PTEN mRNA expression relative to PBS control in HUVEC cells after transfection with various concentrations of compounds 3 and 1 for 48 hours.

[0076] Figure 46A Shown are the percentages of VEGFR2 in HUVEC cells relative to PBS control after 48 hours of transfection with various concentrations of compounds 5 and 1.

[0077] Figure 46B Shown are the percentages of PTEN relative to PBS control in HUVEC cells after transfection with various concentrations of compounds 5 and 1 for 48 hours.

[0078] Figure 47 Shown are the percentages of VEGFR1 mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 4 and 3 for 48 hours under free uptake conditions.

[0079] Figure 48 Shown are the percentages of VEGFR2 mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 6 and 5 for 48 hours under free uptake conditions.

[0080] Figure 49Shown are the percentages of HTT mRNA expression relative to PBS control in undifferentiated SH-SY5Y cells 48 hours after transfection with various concentrations of compounds 29, 28, 27, 2, and 1.

[0081] Figure 50 Shown are the percentages of HTT mRNA expression relative to PBS control in undifferentiated SH-SY5Y cells after exposure of cells to various concentrations of compounds 29, 28, 27, 2, and 1 for 48 hours under free uptake conditions.

[0082] Figure 51 Shown are the percentages of HTT mRNA expression relative to PBS control in differentiated SH-SY5Y cells after exposure of cells to various concentrations of compounds 29, 28, 27, 2, and 1 for 48 hours under free uptake conditions.

[0083] Figure 52 Shown are the percentages of PTEN mRNA expression relative to PBS control in differentiated 3T3L1 adipocytes after exposure of cells to various concentrations of Compounds 2 and 1 for 48 hours under free uptake conditions.

[0084] Figure 53 Shown are the percentages of PTEN mRNA expression in the trabecular meshwork relative to PBS control after cells were exposed to different concentrations of Compounds 2 and 1 for 48 hours under free uptake conditions.

[0085] Figure 54 Shown are the percentages of PTEN mRNA expression relative to PBS control in differentiated primary human skeletal muscle cells after exposure of cells to various concentrations of Compounds 2 and 1 for 96 hours under free uptake conditions.

[0086] Figure 55 Shown are the percentages of PTEN mRNA expression in primary human hepatocytes relative to PBS control after exposure of cells to various concentrations of compounds 1, 2, 7, 8, and 9 for 48 hours under free uptake conditions.

[0087] Figure 56 Shown are the percentages of PTEN mRNA expression in primary human adipocytes after 7 days of incubation for compounds 1, 2, 7, 8, and 9 relative to PBS control.

[0088] Figure 57 Shown are the percentages of PTEN mRNA expression relative to PBS control in differentiated primary human skeletal muscle cells after exposure of cells to various concentrations of Compounds 1, 2, 7, 8, and 9 for 96 hours under free uptake conditions.

[0089] Figure 58 Shown are the percentages of PTEN mRNA expression in primary human stellate cells relative to PBS control after exposure of cells to various concentrations of compounds 1, 2, 7, 8, and 9 for 48 hours under free uptake conditions.

[0090] Figure 59 Shown are the percentages of PTEN mRNA expression in human T cells relative to PBS control after exposure of cells to various concentrations of compounds 2 and 9 for 96 hours under free uptake conditions.

[0091] Figure 60 Shown are the percentages of PTEN mRNA expression seven days after intravitreal injection of different doses of Compound 2 and Compound 37 into mice.

[0092] Figure 61 Shown are quantitative in situ hybridization (RNAscope) results in rats seven days after intravitreal injection of Compound 2. (ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer; 10x, 10x magnification; 40x, 40x magnification).

[0093] Figure 62 Shown are the percentages of PTEN mRNA expression seven days after intravitreal injection of Compound 2 into rats.

[0094] Figure 63 Shown are the percentages of PTEN mRNA expression 48 hours after transfection of conjugated (Compound 2) and unconjugated (Compound 30) PTEN siRNA into HEK293 cells at different doses.

[0095] Figure 64 Shown are the percentages of mRNA expression seven days after intravitreal injection of compounds 2 and 33 into mice (one-way ANOVA, Tukey post hoc test; ***p<0.001, ****p<0.0001, NS, not significant).

[0096] Figure 65 Shown are the percentages of HTT mRNA expression seven days after intravitreal injection of compounds 2 and 29 into mice (one-way ANOVA, Tukey post hoc test; *p<0.05, ****p<0.0001, NS, not significant).

[0097] Figure 66 Shown are the percentages of VEGFR2 mRNA expression 48 hours after transfection of unconjugated VEGFR2 siRNA of compounds 31 and 32 at different doses into BEND cells.

[0098] Figure 67Shown are the percentages of VEGFR2 mRNA expression seven days after intravitreal injection of compounds 2, 34, and 35 into mice (one-way ANOVA, Tukey post hoc test; ***p<0.001, ****p<0.0001, NS, not significant).

[0099] Figure 68 Shown are the percentages of VEGFR2 mRNA expression seven days after intravitreal injection of compounds 2 and 34 into rats (one-way ANOVA, Tukey post hoc test; ****p<0.0001, NS, not significant).

[0100] Figure 69 Shown are the percentages of PTEN mRNA expression seven days after intravitreal injection of compounds 2, 20, 21, and 1 into mice (one-way ANOVA, Tukey post hoc test; ***p<0.001, ****p<0.0001, NS, not significant).

[0101] Figure 70 Shown are the percentages of PTEN mRNA expression seven days after intravitreal injection of compounds 11, 12, 2, 13, and 1 into mice (one-way ANOVA, Tukey post hoc test; **p<0.01, ****p<0.0001, NS, not significant).

[0102] Figure 71 Shown are the percentages of PTEN mRNA expression seven days after intravitreal injection of Compounds 1 and 2 into mice.

[0103] Figure 72 Shown is PTEN mRNA expression in the liver seven days after subcutaneous (SQ) or intravenous (IV) administration of compound 33 to C57B1 / 6 mice.

[0104] Figure 73 Shown are PTEN mRNA expressions in muscle, heart, fat, lung, liver, kidney, and spleen tissues seven days after intravenous administration of Compound 33 to C57B1 / 6 mice.

[0105] Figure 74 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells 48 hours after transfection with various concentrations of compounds 2, 12, 54, 55, and 1.

[0106] Figure 75 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells 48 hours after transfection with various concentrations of compounds 2, 13, 56, 57, and 1.

[0107] Figure 76 Shown are the percentages of PTEN mRNA expression relative to PBS control in HEK293 cells 48 hours after transfection with various concentrations of compounds 12, 13, 58, 59, and 1.

[0108] Figure 77 Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 12, 54, 55, and 1 for 48 hours under free uptake conditions.

[0109] Figure 78 Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 2, 13, 56, 57, and 1 for 48 hours under free uptake conditions.

[0110] Figure 79 Shown are the percentages of PTEN mRNA expression in HUVEC cells relative to PBS control after exposure of cells to various concentrations of compounds 12, 13, 58, 59, and 1 for 48 hours under free uptake conditions.

[0111] Figure 80 Shown are the structures of compounds 72 to 83, which have various combinations of saturated and unsaturated long-chain fatty acid motifs conjugated to the 3′ end of the passenger strand of the siRNA.

[0112] Figure 81 Shown are the structures of compounds 84 to 95, which have various combinations of saturated and unsaturated long-chain fatty acid motifs conjugated to the 3′ end of the passenger strand of the siRNA.

[0113] Figure 82 Shown are the structures of compounds 96 to 107, which have various combinations of saturated and unsaturated long-chain fatty acid motifs conjugated to the 3′ end of the passenger strand of the siRNA.

[0114] Figure 83 Shown are the structures of compounds 108 to 113, which have various combinations of saturated and unsaturated long-chain fatty acid motifs conjugated to the 3' end of the siRNA. DETAILED DESCRIPTION

[0115] definition

[0116] Unless otherwise defined, all technical terms, scientific terms, abbreviations, chemical structures and chemical formulas used herein have the same meaning as those generally understood by those of ordinary skill in the art. The chemical structures and chemical formulas described herein are constructed according to standard chemical valence rules known in the chemical field. Unless otherwise indicated, all patents, applications, published applications and other publications cited herein are incorporated by reference in their entirety. Unless otherwise indicated, conventional methods of mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA technology and pharmacology are employed. In addition, the use of the term "including" and other forms such as "include," "includes," and "included" are not restrictive. As used in this specification, whether in transitional phrases or in the body of the claims, the terms "comprise" and "comprising" will be interpreted as having open-ended meanings. That is, these terms will be interpreted as synonymous with the phrases "having at least" or "comprising at least." When used in the context of a process, the term "comprising" means that the process includes at least the steps described, but may include additional steps. When used in the context of a compound, composition, or device, the term "comprising" means that the compound, composition, or device includes at least the recited features or components, but may also include additional features or components.

[0117] When substituent groups are designated by their conventional chemical formula written from left to right, they also encompass chemically identical substituents that would result from writing the structure from right to left, for example, -CH2O- is equivalent to -OCH2-.

[0118] Unless otherwise indicated, the term "alkyl" by itself or as part of another substituent means a straight (i.e., unbranched) or branched carbon chain (or carbons), or combinations thereof, which may be fully saturated, monounsaturated, or polyunsaturated and may contain monovalent radicals, divalent radicals, and polyvalent radicals. An alkyl group may contain the specified number of carbons (e.g., C1-C 10(represents one to ten carbons). Alkyl is an uncyclized chain. Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, methyl, and homologues and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, and n-octyl. Unsaturated alkyl groups are alkyl groups having one or more double or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1-propynyl and 3-propynyl, 3-butynyl, and higher homologues and isomers. Alkoxy is an alkyl group connected to the rest of the molecule via an oxygen linker (-O-). The alkyl moiety can be an alkenyl moiety. The alkyl moiety can be an alkynyl moiety. The alkyl moiety can be fully saturated. Alkenyl groups may contain more than one double bond and / or one or more triple bonds in addition to one or more double bonds.Alkynyl groups may contain more than one triple bond and / or one or more double bonds in addition to one or more triple bonds.

[0119] In embodiments, the term "cycloalkyl" refers to a monocyclic, bicyclic, or polycyclic cycloalkyl ring system. In embodiments, a monocyclic ring system is a cyclic hydrocarbon group containing 3 to 8 carbon atoms, wherein such a group may be saturated or unsaturated, but not aromatic. In embodiments, a cycloalkyl group is fully saturated. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. A bicyclic cycloalkyl ring system is a bridged monocyclic or fused bicyclic ring. In embodiments, a bridged monocyclic ring contains a monocyclic cycloalkyl ring in which two non-adjacent carbon atoms of the monocyclic ring are connected by an alkylene bridge of between one and three additional carbon atoms (i.e., (CH2) wIn one embodiment, the fused bicyclic cycloalkyl ring system contains a monocyclic cycloalkyl ring fused to a phenyl, monocyclic cycloalkyl, monocyclic cycloalkenyl, monocyclic heterocyclyl, or monocyclic heteroaryl. In one embodiment, the bridged or fused bicyclic cycloalkyl is connected to the parent molecular moiety through any carbon atom contained in the monocyclic cycloalkyl ring. In one embodiment, the cycloalkyl group is optionally substituted with one or two groups that are independently oxo or thio. In an embodiment, the fused bicyclic cycloalkyl is a 5 or 6-membered monocyclic cycloalkyl ring fused to a phenyl ring, a 5 or 6-membered monocyclic cycloalkyl, a 5 or 6-membered monocyclic cycloalkenyl, a 5 or 6-membered monocyclic heterocyclyl, or a 5 or 6-membered monocyclic heteroaryl, wherein the fused bicyclic cycloalkyl is optionally substituted by one or two groups that are independently oxo or thio. In an embodiment, the polycyclic cycloalkyl ring system is a monocyclic cycloalkyl ring (base ring) fused to (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl; or (ii) two other ring systems independently selected from the group consisting of phenyl, bicyclic aryl, monocyclic or bicyclic heteroaryl, monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic cycloalkenyl, and monocyclic or bicyclic heterocyclyl. In an embodiment, the polycyclic cycloalkyl is connected to the parent molecular moiety through any carbon atom contained in the base ring. In an embodiment, the polycyclic cycloalkyl ring system is a monocyclic cycloalkyl ring (base ring) fused to (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl; or (ii) two other ring systems independently selected from the group consisting of phenyl, monocyclic heteroaryl, monocyclic cycloalkyl, monocyclic cycloalkenyl, and monocyclic heterocyclyl. Examples of polycyclic cycloalkyl groups include, but are not limited to, tetradecahydrophenanthrenyl, perhydrophenothiazin-1-yl, and perhydrophenoxazin-1-yl.

[0120] In an embodiment, the cycloalkyl group is a cycloalkenyl group. The term "cycloalkenyl" is used according to its ordinary meaning. In an embodiment, the cycloalkenyl group is a monocyclic, bicyclic, or polycyclic cycloalkenyl ring system. In an embodiment, the monocyclic cycloalkenyl ring system is a cyclic hydrocarbon group containing 3 to 8 carbon atoms, wherein such a group is unsaturated (i.e., contains at least one cyclic carbon-carbon double bond), but is not aromatic. Examples of monocyclic cycloalkenyl ring systems include cyclopentenyl and cyclohexenyl. In an embodiment, the bicyclic cycloalkenyl ring is a bridged monocyclic or fused bicyclic ring. In an embodiment, the bridged monocyclic ring contains a monocyclic cycloalkenyl ring in which two non-adjacent carbon atoms of the monocyclic ring are connected by an alkylene bridge of between one and three additional carbon atoms (i.e., (CH2) wIn one embodiment, the bicyclic cycloalkenyl group is a bridging group of the form of cycloalkyl, wherein w is 1, 2 or 3). Representative examples of bicyclic cycloalkenyl groups include, but are not limited to, norbornenyl and bicyclo[2.2.2]oct2enyl. In an embodiment, the fused bicyclic cycloalkenyl ring system contains a monocyclic cycloalkenyl ring fused to a phenyl, monocyclic cycloalkyl, monocyclic cycloalkenyl, monocyclic heterocyclyl or monocyclic heteroaryl. In an embodiment, the bridged or fused bicyclic cycloalkenyl group is connected to the parent molecular moiety through any carbon atom contained in the monocyclic cycloalkenyl ring. In an embodiment, the cycloalkenyl group is optionally substituted with one or two groups that are independently oxo or thio. In an embodiment, the polycyclic cycloalkenyl ring contains a monocyclic cycloalkenyl ring (base ring) fused to: (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl; or (ii) two ring systems independently selected from the group consisting of phenyl, bicyclic aryl, monocyclic or bicyclic heteroaryl, monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic cycloalkenyl, and monocyclic or bicyclic heterocyclyl. In an embodiment, the polycyclic cycloalkenyl is attached to the parent molecular moiety through any carbon atom contained in the base ring. In an embodiment, the polycyclic cycloalkenyl ring contains a monocyclic cycloalkenyl ring (base ring) fused to: (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl; or (ii) two ring systems independently selected from the group consisting of phenyl, monocyclic heteroaryl, monocyclic cycloalkyl, monocyclic cycloalkenyl, and monocyclic heterocyclyl.

[0121] In an embodiment, heterocycloalkyl is a heterocyclic radical. As used herein, the term "heterocyclic radical" represents monocyclic, bicyclic or polycyclic heterocycles. Heterocyclic radical monocyclic heterocycle is a 3, 4, 5, 6 or 7-membered ring containing at least one heteroatom independently selected from the group consisting of O, N and S, wherein the ring is saturated or unsaturated, but not aromatic. 3 or 4-membered rings contain 1 heteroatom selected from the group consisting of O, N and S. 5-membered rings can contain zero or one double bond and one, two or three heteroatoms selected from the group consisting of O, N and S. 6 or 7-membered rings contain zero, one or two double bonds and one, two or three heteroatoms selected from the group consisting of O, N and S. Heterocyclic radical monocyclic heterocycle is connected to the parent molecular moiety by any carbon atom or any nitrogen atom contained in the heterocyclic radical monocyclic heterocycle. Representative examples of heterocyclyl monocyclic heterocycles include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithiolanyl, 1,3-dithiophenyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiamorpholinyl, 1,1-dioxothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. Heterocyclyl bicyclic heterocycle is a monocyclic heterocycle fused to phenyl, monocyclic cycloalkyl, monocyclic cycloalkenyl, monocyclic heterocycle or monocyclic heteroaryl.Heterocyclyl bicyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained in the monocyclic heterocyclic ring part of the bicyclic system.Representative examples of bicyclic heterocyclyl include but are not limited to 2,3 dihydrobenzofuran 2 base, 2,3 dihydrobenzofuran 3 base, indolin 1 base, indolin 2 base, indolin 3 base, 2,3 dihydrobenzothiophene 2 base, decahydroquinolinyl, decahydroisoquinolinyl, octahydro 1H indolyl and octahydrobenzofuranyl.In an embodiment, the heterocyclyl group is optionally substituted by one or two groups that are independently oxo or thio. In certain embodiments, the bicyclic heterocyclyl is a 5 or 6-membered monocyclic heterocyclyl ring, a 5 or 6-membered monocyclic cycloalkyl, a 5 or 6-membered monocyclic cycloalkenyl, a 5 or 6-membered monocyclic heterocyclyl, or a 5 or 6-membered monocyclic heteroaryl fused to a phenyl ring, wherein the bicyclic heterocyclyl is optionally substituted with one or two groups that are independently oxo or thio. The polycyclic heterocyclyl ring system is a monocyclic heterocyclyl ring (base ring) fused to: (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl; or (ii) two other ring systems independently selected from the group consisting of phenyl, bicyclic aryl, monocyclic or bicyclic heteroaryl, monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic cycloalkenyl, and monocyclic or bicyclic heterocyclyl.The polycyclic heterocyclyl is connected to the parent molecular moiety through any carbon atom or nitrogen atom contained in the base ring. In an embodiment, the polycyclic heterocyclyl ring system is a monocyclic heterocyclyl ring (base ring) fused to: (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl and bicyclic heterocyclyl; or (ii) two other ring systems independently selected from the group consisting of phenyl, monocyclic heteroaryl, monocyclic cycloalkyl, monocyclic cycloalkenyl and monocyclic heterocyclyl. Examples of polycyclic heterocyclyl groups include, but are not limited to, 10H-phenothiazin-10-yl, 9,10-dihydroacridin-9-yl, 9,10-dihydroacridin-10-yl, 10H-phenoxazin-10-yl, 10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl, 1,2,3,4-tetrahydropyrido[4,3-g]isoquinolin-2-yl, 12H-benzo[b]phenoxazin-12-yl, and dodecahydro-1H-carbazol-9-yl.

[0122] Unless otherwise stated, the term "alkylene" by itself or as part of another substituent refers to a divalent radical derived from an alkyl group, such as, but not limited to, -CH2CH2CH2CH2-. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those having 10 or fewer carbon atoms being preferred herein. "Lower alkyl" or "lower alkylene" is a short-chain alkyl or alkylene group, typically having eight or fewer carbon atoms. Unless otherwise stated, the term "alkenylene" by itself or as part of another substituent refers to a divalent radical derived from an alkene group.

[0123] Unless otherwise indicated, the term "heteroalkyl" by itself or in combination with another term refers to a stable straight or branched chain or combination thereof, comprising at least one carbon atom and at least one heteroatom (e.g., O, N, S, Si, or P), and wherein the nitrogen and sulfur atoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. The heteroatom (e.g., O, N, S, Si, or P) may be located at any interior position of the heteroalkyl group or at a position where the alkyl group is attached to the rest of the molecule. A heteroalkyl group is an uncyclized chain. Examples include, but are not limited to: -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2, -S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, -O-CH3, -O-CH2-CH3, and -CN. Up to two or three heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. A heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P). Unless otherwise stated, the term "heteroalkenyl" by itself or in combination with another term refers to a heteroalkyl group comprising at least one double bond. The heteroalkyl group may optionally include more than one double bond and / or one or more triple bonds in addition to one or more double bonds. Unless otherwise stated, the term "heteroalkynyl" by itself or in combination with another term refers to a heteroalkyl group comprising at least one triple bond. The heteroalkynyl group may optionally include more than one triple bond and / or one or more double bonds in addition to one or more triple bonds.

[0124] Similarly, unless otherwise indicated, the term "heteroalkylene" by itself or as part of another substituent refers to a divalent radical derived from a heteroalkyl group, such as, but not limited to, -CH2-CH2-S-CH2-CH2- and -CH2-S-CH2-CH2-NH-CH2-. For heteroalkylene groups, heteroatoms may also occupy one or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.). Furthermore, for alkylene and heteroalkylene linking groups, the orientation of the linking group is not affected by the direction in which the formula of the linking group is written. For example, the formula -C(O)2R'- refers to both -C(O)2R'- and -R'C(O)2-. As described above, heteroalkyl groups as used herein include those groups that are attached to the rest of the molecule through a heteroatom, such as -C(O)R', -C(O)NR', ​​-NR'R", -OR', -SR', and / or -S02R'. Where "heteroalkyl" is recited, followed by a specific heteroalkyl group, such as -NR'R", etc., it is understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited for added clarity. Thus, the term "heteroalkyl" should not be construed herein to exclude specific heteroalkyl groups, such as -NR'R", etc.

[0125] Unless otherwise indicated, the terms "cycloalkyl" and "heterocycloalkyl," by themselves or in combination with other terms, refer to cyclic forms of "alkyl" and "heteroalkyl," respectively. Cycloalkyl and heterocycloalkyl groups are not aromatic. Furthermore, for heterocycloalkyl groups, a heteroatom may occupy the position at which the heterocycle is attached to the rest of the molecule. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, and cycloheptyl. Examples of heterocycloalkyl groups include, but are not limited to, 1-(1,2,5,6-tetrahydropyridinyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothiophen-2-yl, tetrahydrothiophen-3-yl, 1-piperazinyl, and 2-piperazinyl. "Cycloalkylene" and "heterocycloalkylene" alone or as part of another substituent refer to a divalent radical derived from cycloalkyl and heterocycloalkyl, respectively.

[0126] Unless otherwise indicated, the term "halo" or "halogen" by itself or as part of another substituent refers to a fluorine, chlorine, bromine, or iodine atom. In addition, terms such as "haloalkyl" are intended to encompass monohaloalkyl and polyhaloalkyl. For example, the term "halo(C1-C4)alkyl" includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0127] Unless otherwise indicated, the term "acyl" means -C(O)R, where R is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0128] Unless otherwise indicated, the term "aryl" refers to a polyunsaturated aromatic hydrocarbon substituent, which can be a single ring or multiple rings (preferably 1 to 3 rings) fused together (i.e., fused ring aromatics) or covalently linked. A fused ring aromatic refers to multiple rings fused together, wherein at least one fused ring is an aryl ring. The term "heteroaryl" refers to an aryl group (or ring) containing at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom is optionally quaternized. Therefore, the term "heteroaryl" includes fused ring heteroaryl groups (i.e., multiple rings fused together, wherein at least one fused ring is a heteroaromatic ring). 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Similarly, 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And 6,5- fused ring heteroarylene refers to two rings fused together, one of which has 6 members and the other has 5 members, and at least one of which is a heteroaryl ring. The heteroaryl group can be connected to the rest of the molecule through carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidinyl, benzothiazolyl, benzoxazolylbenzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothienyl, isoquinolyl, quinoxalinyl, quinolyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl Substituents for each of the above aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. "Arylene" and "heteroarylene," alone or as part of another substituent, mean a divalent radical derived from aryl and heteroaryl, respectively. A heteroaryl group substituent may be bonded to a ring heteroatom nitrogen -O-.

[0129] Spirocycle is two or more rings, wherein adjacent rings are connected by a single atom.The independent ring in spirocycle can be identical or different.The independent ring in spirocycle can be substituted or unsubstituted, and can have the substituent different from other independent rings in one group of spirocycle.When not being a part of spirocycle, the possible substituent of the independent ring in spirocycle is the possible substituent of same ring (such as the substituent of cycloalkyl or heterocycloalkyl ring).Spirocycle can be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene, and the independent ring in spirocyclic group can be any ring just listed above, comprising all rings with a type (such as, all rings are substituted heterocycloalkylene, wherein each ring can be the same or different substituted heterocycloalkylene).When mentioning spirocycle system, heterocycle spirocycle represents spirocycle, wherein at least one ring is heterocycle, and wherein each ring can be different rings.When mentioning spirocycle system, the substituted spirocycle represents at least one ring is substituted, and each substituent can be optionally different.

[0130] symbol Indicates the point of attachment of a chemical moiety to the rest of a molecule or chemical formula.

[0131] The term "oxo" as used herein refers to an oxygen double bonded to a carbon atom.

[0132] The term "alkylarylene" refers to an arylene moiety covalently bonded to an alkylene moiety (also referred to herein as an alkylene linker). In an embodiment, the alkylarylene group has the formula:

[0133]

[0134] The alkylarylene moiety can be substituted (e.g., with a substituent group) on the alkylene moiety or arylene linker (e.g., at carbon 2, 3, 4, or 6) with halogen, oxo, -N, -CF, -CCl, -CBr, -CI, -CN, -CHO, -OH, -NH, -COOH, -CONH, -NO, -SH, -SOCH, -SOH, -OSOH, -SONH, -NHNH, -ONH, -NHC(O)NHNH, substituted or unsubstituted C1-C5 alkyl, or substituted or unsubstituted 2-5 membered heteroalkyl. In an embodiment, the alkylarylene group is unsubstituted.

[0135] Each of the above terms (eg, "alkyl," "heteroalkyl," "cycloalkyl," "heterocycloalkyl," "aryl," and "heteroaryl") encompasses both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each radical are provided below.

[0136] Substituents for alkyl and heteroalkyl radicals (including those groups commonly referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, -OR', =O, =NR', =N-OR', -NR'R", -SR', -halogen, -SiR'R"R"', -OC(O)R', -C(O)R', -CO2R', -CONR'R" , -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R"')=NR"", -NR-C(NR'R ”)=NR”’, -S(O)R’, -S(O)2R’, -S(O)2NR’R”, -NRSO2R’, -NR’NR”R”’, -ONR’R”, -NR’C(O)NR”NR”’R”” , -CN, -NO2, -NR'SO2R", -NR'C(O)R", -NR'C(O)-OR", -NR'OR", the number of which ranges from zero to (2m'+1), where m' is the total number of carbon atoms in such radicals. R, R', R", R'' and R"" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., substituted by 1 -3 halogen-substituted aryl), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy or thioalkoxy group or arylalkyl group. When the compounds described herein contain more than one R group, for example, when more than one of these groups is present, each R group is independently selected to be each R', R", R"' and R"" group. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-membered ring, a 5-membered ring, a 6-membered ring or a 7-membered ring. For example, -NR'R" includes but is not limited to 1-pyrrolidinyl and 4-morpholinyl. Based on the above discussion of substituents, those skilled in the art will understand that the term "alkyl" refers to a group containing a carbon atom combined with a group other than a hydrogen group, such as a haloalkyl (e.g., -CF3 and -CH2CF3) and an acyl (e.g., -C(O)CH3, -C(O)CF3, -C(O)CH2OCH3, etc.).

[0137] Similar to the substituents described for the alkyl radicals, the substituents for the aryl and heteroaryl groups are varied and are selected from, for example: -OR', -NR'R", -SR', -halogen, -SiR'R"R"', -OC(O)R', -C(O)R', -C02R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R"')=NR"", -NR-C(NR'R")=NR"', -S(O)R', -S(O)2R', -S(O)2NR'R", -NRSO2R', -NR'NR"R"', -ONR'R", -NR'C(O)NR"NR"'R"', - CN, -NO2, -R', -N3, -CH(Ph)2, fluoro(C1-C4)alkoxy and fluoro(C1-C4)alkyl, -NR'S02R", -NR'C(O)R", -NR'C(O)-OR", -NR'OR", ranging from zero to the total number of open valences on the aromatic ring system; and wherein R', R", R''" and R"" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. When the compounds described herein contain more than one R group, for example, when more than one of these groups is present, each R group is independently selected from each R', R", R''" and R"" group.

[0138] The substituents of the ring (such as cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylidene, heterocycloalkylidene, arylidene or heteroarylidene) can be described as substituents on the ring, rather than substituents on the specific atoms of the ring (commonly referred to as floating substituents). In this case, the substituent can be connected to any ring atom (following chemical valence rules), and in the case of fused rings or spirocycles, the substituent described as being associated with a member of the fused ring or spirocycle (floating substituent on a single ring) can be a substituent on any fused ring or spirocycle (floating substituent on multiple rings). When the substituent is connected to the ring rather than on a specific atom (floating substituent), and the subscript of the substituent is an integer greater than one, multiple substituents can be on the same atom, on the same ring, on different atoms, on different fused rings, on different spirocycles, and each substituent can be optionally different. When the point of attachment of the ring to the rest of the molecule is not limited to a single atom (floating substituent), the point of attachment can be any atom of the ring, and in the case of fused rings or spirocycles, it can be any atom of any fused ring or spirocycle, while following chemical valence rules. Where a ring, fused ring, or spiro ring contains one or more ring heteroatoms, and the ring, fused ring, or spiro ring shows one or more floating substituents (including but not limited to the point of attachment to the rest of the molecule), the floating substituent may be bonded to the heteroatom. Where a ring heteroatom is shown bonded to one or more hydrogens in a structure or formula having a floating substituent (e.g., a ring nitrogen having two bonds to ring atoms and a third bond to a hydrogen), when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen while adhering to chemical valence rules.

[0139] Two or more substituents can be optionally connected to form aryl, heteroaryl, cycloalkyl or heterocycloalkyl groups. Such so-called cyclic substituents are usually (although not necessarily) found to be connected to the cyclic base structure. In one embodiment, the cyclic substituent is connected to the adjacent members of the base structure. For example, two cyclic substituents connected on the adjacent members of the cyclic base structure form a condensed ring structure. In another embodiment, the cyclic substituent is connected to the single member of the base structure. For example, two cyclic substituents connected on the single member of the cyclic base structure form a spirocyclic structure. In another embodiment, the cyclic substituent is connected to the non-adjacent members of the base structure.

[0140] Two substituents on adjacent atoms of an aryl or heteroaryl ring may optionally form a ring of the formula -TC(O)-(CRR') q -U-, wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer from 0 to 3. Alternatively, two substituents on adjacent atoms of the aryl or heteroaryl ring may be optionally replaced by a substituent of the formula -A-(CH2) r-B-, wherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)2-, -S(O)2NR'-, or a single bond, and r is an integer from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced by a double bond. Alternatively, two substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced by a substituent of the formula -(CRR') s -X'-(C”R”R”') d -, wherein s and d are independently integers from 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -S(O)2- or -S(O)2NR'-. The substituents R, R', R" and R'" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.

[0141] As used herein, the term "heteroatom" or "ring heteroatom" refers to groups including oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).

[0142] As used herein, a "substituent group" refers to a group selected from the following moieties:

[0143] (A) Oxo, halogen, -CF3, -CCl3, -CBr3, -CI3, -CHF2, -CHCl2, -CHBr2, -CHI2, -CH2F, -CH2Cl, -CH2Br, -CH2I, -CN, -N3, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -OCF3, -OCCl3, -OC Br3, -OCI3, -OCHF2, -OCHCl2, -OCHBr2, -OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, -OCHI, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C 10 Aryl, C 10aryl or phenyl) or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and

[0144] (B) an alkyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group substituted with at least one substituent selected from the group consisting of:

[0145] (i) oxo, halogen, -CF3, -CCl3, -CBr3, -CI3, -CHF2, -CHCl2, -CHBr2, -CHI2, -CH2F, -CH2Cl, -CH2Br, -CH2I, -CN, -N3, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -OCF3, -OCCl3, -OC Br3, -OCI3, -OCHF2, -OCHCl2, -OCHBr2, -OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, -OCHI, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C 10 Aryl, C 10 aryl or phenyl) or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and

[0146] (ii) an alkyl group, a heteroalkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group substituted with at least one substituent selected from the group consisting of:

[0147] (a) oxo, halogen, -CF3, -CCl3, -CBr3, -CI3, -CHF2, -CHCl2, -CHBr2, -CHI2, -CH2F, -CH2Cl, -CH2Br, -CH2I, -CN, -N3, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -OCF3, -OCCl3, -OC Br3, -OCI3, -OCHF2, -OCHCl2, -OCHBr2, -OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, -OCHI, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C 10 Aryl, C 10 aryl or phenyl) or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and

[0148] (b) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl substituted with at least one substituent selected from the group consisting of oxo, halogen, -CF3, -CCl3, -CBr3, -CI3, -CHF2, -CHCl2, -CHBr2, -CHI2, -CH2F, -CH2Cl, -CH2Br, -CH2I, -CN, -N3, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SCH3, -SO3H, -SO4H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -N -HOH, -OCF3, -OCCl3, -OCBr3, -OCI3, -OCHF2, -OCHCl2, -OCHBr2, -OCHI2, -OCH2F, -OCH2Cl, -OCH2Br, -OCHI, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C 10 Aryl, C 10 aryl or phenyl) or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl).

[0149] As used herein, "a substituent group of limited size" or "a substituent group of limited size" refers to a group selected from all substituents described above for a "substituent group", wherein each substituted or unsubstituted alkyl group is a substituted or unsubstituted C1-C 20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 20-membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3- to 8-membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C 10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5- to 10-membered heteroaryl.

[0150] As used herein, a “lower substituent” or “lower substituent group” refers to a group selected from all substituents described above for the “substituent group”, wherein each substituted or unsubstituted alkyl group is a substituted or unsubstituted C1-C8 alkyl group, each substituted or unsubstituted heteroalkyl group is a substituted or unsubstituted 2- to 8-membered heteroalkyl group, each substituted or unsubstituted cycloalkyl group is a substituted or unsubstituted C3-C7 cycloalkyl group, each substituted or unsubstituted heterocycloalkyl group is a substituted or unsubstituted 3- to 7-membered heterocycloalkyl group, and each substituted or unsubstituted aryl group is a substituted or unsubstituted C6-C8 10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5- to 9-membered heteroaryl.

[0151] In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and / or substituted or unsubstituted heteroarylene) is unsubstituted (e.g., unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted alkylene, unsubstituted heteroalkylene, unsubstituted cycloalkylene, unsubstituted heterocycloalkylene, unsubstituted arylene, and / or unsubstituted heteroarylene, respectively). In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and / or substituted or unsubstituted heteroarylene) is substituted (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene, respectively).

[0152] In an embodiment, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one substituent group, wherein if the substituted moiety is substituted with a plurality of substituent groups, each substituent group may optionally be different. In an embodiment, if the substituted moiety is substituted with a plurality of substituent groups, each substituent group is different.

[0153] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one size-restricted substituent group, wherein if the substituted moiety is substituted with multiple size-restricted substituent groups, each size-restricted substituent group can optionally be different. In embodiments, if the substituted moiety is substituted with multiple size-restricted substituent groups, each size-restricted substituent group is different.

[0154] In an embodiment, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one lower substituent group, wherein if the substituted moiety is substituted with multiple lower substituent groups, each lower substituent group may optionally be different. In an embodiment, if the substituted moiety is substituted with multiple lower substituent groups, each lower substituent group is different.

[0155] In an embodiment, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one substituent group, size-restricted substituent group, or low-level substituent group; wherein if the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-restricted substituent groups, and low-level substituent groups, each substituent group, size-restricted substituent group, and / or low-level substituent group may optionally be different. In an embodiment, if the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-restricted substituent groups, and low-level substituent groups, each substituent group, size-restricted substituent group, and / or low-level substituent group is different.

[0156] In embodiments of compounds herein, each substituted or unsubstituted alkyl group can be a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C1-C 20alkyl, each substituted or unsubstituted heteroalkyl is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted 2- to 20-membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted 3- to 8-membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C6-C 10 Aryl, and / or each substituted or unsubstituted heteroaryl is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted 5- to 10-membered heteroaryl. In the embodiments herein, each substituted or unsubstituted alkylene is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C1-C 20 alkylene, each substituted or unsubstituted heteroalkylene is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted 2- to 20-membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C3-C8 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted 3- to 8-membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C6-C8 10 The arylene group, and / or each substituted or unsubstituted heteroarylene group is a substituted (eg, substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted 5- to 10-membered heteroarylene group.

[0157] In embodiments, each substituted or unsubstituted alkyl group is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C1-C8 alkyl group, each substituted or unsubstituted heteroalkyl group is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted 2- to 8-membered heteroalkyl group, each substituted or unsubstituted cycloalkyl group is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C3-C7 cycloalkyl group, each substituted or unsubstituted heterocycloalkyl group is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted 3- to 7-membered heterocycloalkyl group, each substituted or unsubstituted aryl group is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C6-C 10 The aryl group, and / or each substituted or unsubstituted heteroaryl group is a substituted (eg, substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted 5- to 9-membered heteroaryl group. In embodiments, each substituted or unsubstituted alkylene group is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C1-C8 alkylene group, each substituted or unsubstituted heteroalkylene group is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted 2- to 8-membered heteroalkylene group, each substituted or unsubstituted cycloalkylene group is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C3-C7 cycloalkylene group, each substituted or unsubstituted heterocycloalkylene group is a substituted or unsubstituted 3- to 7-membered heterocycloalkylene group, each substituted or unsubstituted arylene group is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted C6-C 10 Arylene, and / or each substituted or unsubstituted heteroarylene is a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted 5- to 9-membered heteroarylene. In the embodiments, the compound is a chemical substance listed in the Examples section, Figures, or Tables below.

[0158] Certain compounds provided herein have asymmetric carbon atoms (optical or chiral centers) or double bonds; enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomeric forms (which can be defined as (R)- or (S)- or (D)- or (L)- of an amino acid in terms of absolute stereochemistry) and individual isomers are included within the scope of the present disclosure. The compounds provided herein do not include those compounds known in the art that are too unstable to synthesize and / or separate. The compounds provided herein include racemic and optically pure forms of the compounds. Optically active (R)- and (S)- or (D)- and (L)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless otherwise indicated, the compounds are intended to encompass both E and Z geometric isomers.

[0159] As used herein, the term "isomers" refers to compounds that have the same number and kind of atoms, and therefore the same molecular weight, but differ in the structural arrangement or configuration of the atoms.

[0160] As used herein, the term "tautomer" refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another.

[0161] It will be apparent to those skilled in the art that certain compounds provided herein may exist in tautomeric forms, and all such tautomeric forms of the compounds are within the scope of the present disclosure.

[0162] When the compounds disclosed herein have at least one chiral center, they can exist as individual enantiomers and diastereomers, or as mixtures of such isomers, including racemates. The separation of individual isomers or the selective synthesis of individual isomers is achieved by applying various methods well known to those skilled in the art. Unless otherwise indicated, all such isomers and mixtures thereof are included within the scope of the compounds disclosed herein. Unless otherwise indicated, the structures described herein are also meant to include all stereochemical forms of the structure; that is, the (R) configuration and the (S) configuration of each asymmetric center. Therefore, it is generally recognized by those skilled in the art that single stereochemical isomers of stable compounds of the present invention, as well as enantiomers and diastereomeric mixtures, are within the scope of the present disclosure.

[0163] Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, except for the replacement of hydrogen by deuterium or tritium, 18 F instead of fluoride, or with a rich 13 C or 14Compounds having this structure except where the carbon of C is substituted for carbon are within the scope of this disclosure.

[0164] The compounds provided herein may also contain unnatural proportions of atomic isotopes at one or more atoms comprising such compounds. For example, the compounds may be modified with radioactive isotopes such as, for example, tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C)) is radiolabeled. All isotopic variations of the compounds provided herein, whether radioactive or not, are encompassed by the present disclosure.

[0165] It should be noted that throughout the application, alternatives are written in Markush groups, e.g., each amino acid position contains more than one amino acid. It is specifically contemplated that each member of the Markush group should be considered individually, thereby comprising another embodiment, and the Markush group should not be construed as a single unit.

[0166] "Analog" or "analogue" is used according to its ordinary meaning in chemistry and biology and refers to a compound that is structurally similar to another compound (the so-called "reference" compound) but differs in composition, for example, in the replacement of an atom by an atom of a different element, or in the presence of a particular functional group, or in the replacement of one functional group by another functional group, or in the absolute stereochemistry of one or more chiral centers of the reference compound. Thus, an analog is a compound that is similar or comparable in function and appearance but differs in structure or origin from the reference compound.

[0167] As used herein, the term "a" or "an" means one or more. In addition, as used herein, the phrase "substituted with" means that the specified group may be substituted with one or more of any or all of the specified substituents. For example, in a group such as an alkyl or heteroaryl group "substituted with unsubstituted C1-C 20 In the case of "substituted with alkyl or unsubstituted 2 to 20 membered heteroalkyl", the group may contain one or more unsubstituted C1-C 20 alkyl, and / or one or more unsubstituted 2- to 20-membered heteroalkyl groups.

[0168] Where a moiety is substituted with an R substituent, the group may be referred to as "R-substituted". Where a moiety is R-substituted, the moiety is substituted with at least one R substituent, and each R substituent is optionally different. Where a specific R group is present in the description of a chemical genus such as Formula (I), Roman decimal notation may be used to distinguish each appearance of that specific R group. For example, where multiple R 13 In the case of a substituent, each R 13Substituents can be divided into R 13.1 、R 13.2 、R 13.3 、R 13.4 etc., where R 13.1 、R 13.2 、R 13.3 、R 13.4 Each of the above in R 13 As used herein, the term "a" or "an" means one or more. In addition, as used herein, the phrase "substituted by" means that a particular group may be substituted by one or more of any or all of the specified substituents. For example, in a group such as an alkyl or heteroaryl group "substituted by an unsubstituted C1-C 20 In the case of "substituted with alkyl or unsubstituted 2 to 20 membered heteroalkyl", the group may contain one or more unsubstituted C1-C 20 alkyl, and / or one or more unsubstituted 2- to 20-membered heteroalkyl groups.

[0169] The descriptions of the compounds provided herein are subject to the principles of chemical bonding known to those skilled in the art. Thus, where a group may be substituted with one or more of a variety of substituents, such substitutions are selected so as to conform to the principles of chemical bonding and to yield compounds that are not inherently unstable and / or that are known to those skilled in the art to be potentially unstable under environmental conditions such as aqueous, neutral, and several known physiological conditions. For example, a heterocycloalkyl or heteroaryl group is attached to the rest of the molecule via a ring heteroatom, according to the principles of chemical bonding known to those skilled in the art, thereby avoiding inherently unstable compounds.

[0170] The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness and properties of the compound and is not biologically or otherwise undesirable for use in medicine. In many cases, the compounds herein are capable of forming acid and / or base salts due to the presence of amino and / or carboxyl groups or similar groups. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; ammonium, potassium, sodium, calcium, and magnesium salts are particularly preferred. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, basic ion exchange resins, and the like, particularly such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. Many such salts are known in the art, as described in WO 87 / 05297 to Johnston et al., published September 11, 1987, incorporated herein by reference in its entirety.

[0171] "Contacting" is used according to its ordinary meaning and refers to the process of allowing at least two different substances (e.g., compounds, biomolecules, or cells) to come into close enough proximity to react, interact, or come into physical contact. For example, contacting includes the process of allowing a compound to come into close enough proximity to a cell to bind to a cell surface receptor.

[0172] As used herein, "contacting a cell" refers to a situation in which a compound or other composition of matter is in direct contact with a cell, or close enough to induce a desired biological effect in the cell.

[0173] As used herein, the term "free uptake conditions" refers to conditions in which unmodified oligonucleotides do not substantially enter the cell. For example, such free uptake conditions can be conditions in which there is little or no transfection reagent, electroporation technology or other conditions for promoting the entry of compounds into cells. Free uptake conditions can be conditions in which the lack of lipid-conjugated siRNA does not substantially enter the cell, such as incubation in standard culture medium under standard conditions for a particular type of cell. The example of standard culture medium conditions for free uptake can be a range from 0.5% to 10%, for example, 1% to 5% fetal bovine serum (FBS). In other examples, standard culture medium is serum-free.

[0174] The term "activator" refers to a compound, composition, or substance that detectably increases the expression or activity of a given gene or protein. For example, an activator can increase expression or activity by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to a control lacking the activator.

[0175] As defined herein, the terms "inhibition," "inhibit," "inhibiting," and the like refer to negatively affecting (e.g., reducing) an activity or function relative to the activity or function in the absence of the inhibitor. In embodiments, inhibition refers to negatively affecting (e.g., reducing) the concentration or level of a biomolecule, such as a protein or mRNA, relative to the concentration or level of the biomolecule in the absence of the inhibitor. For example, inhibition comprises reducing the level of mRNA expression in a cell. In embodiments, inhibition refers to a reduction in the activity of a particular biomolecule target, such as a protein target or an mRNA target. Thus, inhibition comprises at least partially, partially, or completely blocking stimulation, reducing, preventing, or delaying activation or inactivation, desensitizing, or downregulating the amount of a signal transduction or enzyme activity or biomolecule. In embodiments, inhibition refers to a reduction in the activity of a target biomolecule resulting from a direct interaction (e.g., binding of the inhibitor to a target protein). In embodiments, inhibition refers to a reduction in the activity of a target biomolecule due to an indirect interaction (e.g., binding of the inhibitor to a protein that activates the target protein, thereby preventing activation of the target protein).

[0176] The term "inhibitor" also refers to a compound, composition, or substance that can detectably reduce the expression or activity of a given gene or protein. For example, an inhibitor can reduce expression or activity by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to a control lacking the inhibitor. Inhibitors include, for example, synthetic or biological molecules, such as oligonucleotides.

[0177] As used herein, the terms "expression" and "gene expression" refer to the steps involved in translating nucleic acid into protein, including mRNA expression and protein expression. Expression can be detected using conventional techniques for detecting nucleic acid or protein (e.g., PCR, ELISA, Southern blotting, Western blotting, flow cytometry, FISH, immunofluorescence, immunohistochemistry).

[0178] An "effective amount" is an amount sufficient to achieve the purpose of the compound (e.g., to achieve the effect of its administration, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signal transduction pathway, or alleviate one or more symptoms of a disease or condition) relative to the absence of the compound. As used herein, an "activity-reducing amount" refers to the amount of antagonist required to reduce the activity of an enzyme relative to the absence of the antagonist. As used herein, a "function-disrupting amount" refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist.

[0179] The term "cell" is used herein in its ordinary sense as understood by those of ordinary skill in the art. The cell can be prokaryotic or eukaryotic. Prokaryotic cells include, but are not limited to, bacteria. Eukaryotic cells include, but are not limited to, yeast cells, plant cells, and animal cells (including human cells). Cells can be identified by methods well known in the art, including, for example, the presence of an intact membrane, staining with a specific dye, the ability to produce offspring, or, in the case of gametes, the ability to combine with a second gamete to produce viable offspring. In an embodiment, the cell can be from an immortalized cell line. In an embodiment, the cell can be a primary cell. In an embodiment, the cell is in vitro. In an embodiment, the cell is in vivo. In an embodiment, the cell is isolated.

[0180] As used herein, the term "in vivo" refers to a process that occurs within the body of a subject.

[0181] As used herein, the term "subject" refers to a human or non-human animal selected for treatment or therapy. In an embodiment, the subject is a human.

[0182] As used herein, the term "ex vivo" refers to a process that occurs in isolated tissues or cells in vitro, wherein the treated tissues or cells comprise primary cells. As is known in the art, any medium used in the process may be aqueous and non-toxic so as not to render the tissue or cells inviable. In an embodiment, the ex vivo process is performed in vitro using primary cells.

[0183] The term "administering" means providing an agent or composition to a subject and encompasses administration by a medical professional and self-administration.

[0184] The term "therapy" refers to the application of one or more specific procedures to improve at least one indicator or disease or condition. In an embodiment, the specific procedure is the administration of one or more pharmaceutical agents.

[0185] The term "modulate" is used herein in its ordinary sense as understood by one of ordinary skill in the art, and thus refers to the act of altering or changing one or more properties. For example, in the context of the effect of a modulator on a target molecule, modulating means changing by increasing or decreasing a property or function of the target molecule or the amount of the target molecule. A modulator of a disease reduces a symptom, cause, or characteristic of the target disease.

[0186] The terms "nucleic acid," "oligonucleotide," and "polynucleotide" refer to compounds containing at least two covalently linked nucleotide monomers. These terms encompass single-stranded and double-stranded nucleic acids, nucleic acids, oligonucleotides, and polynucleotides, including single-stranded DNA, double-stranded DNA, single-stranded RNA, double-stranded RNA, single-stranded and double-stranded molecules containing DNA and RNA nucleotides, and modified forms thereof. Oligonucleotide refers to a polymer of shorter length and is typically about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more nucleotides in length, with a maximum length of about 100 nucleotides. Nucleic acids and polynucleotides are typically polymers of nucleotides of longer length, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000. A "residue" of a nucleic acid, oligonucleotide, or polynucleotide refers to a nucleotide monomer of the compound. "Residue" and "monomer" are used interchangeably herein. In an embodiment, an oligonucleotide can be used for RNA silencing. In an embodiment, the oligonucleotide may comprise DNA, a locked nucleic acid (LNA), a bicyclic nucleic acid (BNA), or a phosphorodiamidate morpholino oligomer (PMO), or a modification thereof. In an embodiment, the oligonucleotide comprises one or more 2'-O-methoxyethyl residues, 2'-O-methyl residues, and / or 2'-fluoro residues. In an embodiment, the oligonucleotide comprises a phosphorothioate bond.

[0187] Non-limiting examples of oligonucleotides include double-stranded oligonucleotides, modified double-stranded oligonucleotides, single-stranded oligonucleotides, modified single-stranded oligonucleotides, antisense oligonucleotides, siRNA, microRNA mimics, stem-loop structures, single-stranded siRNA, RNase H oligonucleotides, anti-microRNA oligonucleotides, steric blocking oligonucleotides, CRISPR guide RNA, and aptamers.

[0188] Non-limiting examples of polynucleotides include genes, gene fragments, exons, introns, intergenic DNA (including but not limited to heterochromatic DNA), messenger RNA (mRNA), long non-coding RNA, transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA sequences, and isolated RNA sequences. The polynucleotides useful in the methods of the present disclosure may comprise natural nucleic acid sequences and variants thereof, artificial nucleic acid sequences, or combinations of such sequences.

[0189] As used herein, "nucleoside" refers to a glycosyl compound consisting of a core base and a 5-membered ring sugar (e.g., ribose or deoxyribose). A nucleoside may include a base such as A, C, G, T, U, or its analogs. A nucleoside may be modified on the base and / or sugar. In one embodiment, a nucleoside is a deoxyribonucleoside. In another embodiment, a nucleoside is a ribonucleoside.

[0190] As used herein, " nucleotide " refers to nucleoside-5 '-polyphosphate compound or its structural analog, which can be incorporated (for example, partially as nucleoside-5 '-monophosphate or its derivatives) to extend the growing nucleic acid chain (such as primer) by nucleic acid polymerase. Nucleotide can include bases such as A, C, G, T, U or its analogs, and can include 2, 3, 4, 5, 6, 7, 8 or more phosphates in the phosphate group. Nucleotide can be modified at one or more places in the base, sugar or phosphate group. Nucleotide can have a part that is directly or connected by a joint. In one embodiment, nucleotide is a deoxyribonucleotide. In another embodiment, nucleotide is a ribonucleotide.

[0191] As used herein, "nucleotide analogs" shall mean analogs of A, G, C, T, or U (i.e., analogs of nucleotides comprising the bases A, G, C, T, or U) that include a phosphate group and can be recognized by DNA or RNA polymerase (whichever is applicable) and incorporated into a chain of DNA or RNA (whichever is applicable). Examples of nucleotide analogs include, but are not limited to, 7-deaza-adenine, 7-deaza-guanine, analogs of the deoxynucleotides described herein, analogs in which a label is attached to the 5-position of cytosine or thymine or the 7-position of deaza-adenine or deaza-guanine via a cleavable linker, and analogs in which a small chemical moiety is used to block the -OH group at the 3'-position of the deoxyribose sugar. Nucleotide analogs and DNA polymerase-based DNA sequencing are also described in U.S. Patent No. 6,664,079, which is incorporated herein by reference in its entirety for all purposes.

[0192] The term "base" and "nucleobase" as used herein in the context of oligonucleotides, nucleic acids or polynucleotides refers to a purine or pyrimidine compound or a derivative thereof, which can be a component of a nucleic acid (i.e., DNA or RNA, or a derivative thereof). In an embodiment, a nucleobase is a derivative (e.g., a base analog) of a naturally occurring DNA or RNA base. In an embodiment, a nucleobase is a derivative (e.g., a base analog) of a naturally occurring DNA or RNA base, which can optionally be substituted. In an embodiment, a nucleobase is a hybridization base. In an embodiment, a nucleobase is a hybridization base, which can optionally be substituted. In an embodiment, a nucleobase hybridizes with a complementary base. In an embodiment, a nucleobase is capable of forming at least one hydrogen bond with a complementary nucleobase (e.g., forming an adenine hydrogen bond with thymine, forming an adenine hydrogen bond with uracil, or forming a guanine pair with cytosine). Non-limiting examples of nucleobases include cytosine or a derivative thereof (e.g., a cytosine analog), guanine or a derivative thereof (e.g., a guanine analog), adenine or a derivative thereof (e.g., an adenine analog), thymine or a derivative thereof (e.g., a thymine analog), uracil or a derivative thereof (e.g., a uracil analog), hypoxanthine or a derivative thereof (e.g., a hypoxanthine analog), xanthine or a derivative thereof (e.g., a xanthine analog), 7-methylguanine or a derivative thereof (e.g., a 7-methylguanine analog), deazaadenine or a derivative thereof (e.g., a deazaadenine analog), deazaguanine or a derivative thereof (e.g., deazaguanine), deazahypoxanthine or a derivative thereof, 5,6-dihydrouracil or a derivative thereof (e.g., a 5,6-dihydrouracil analog), 5-methylcytosine or a derivative thereof (e.g., a 5-methylcytosine analog), or a 5-hydroxymethylcytosine or a derivative thereof (e.g., a 5-hydroxymethylcytosine analog) moiety. In embodiments, the nucleobase is adenine, guanine, hypoxanthine, xanthine, theobromine, caffeine, uric acid, or isoguanine, which may be optionally substituted or modified. In embodiments, the nucleobase is It may be optionally substituted or modified.

[0193] Oligonucleotides, nucleic acids and polynucleotides can contain non-specific sequences. As used herein, the term "non-specific sequence" refers to a sequence containing a series of residues that are not designed to be complementary to any other sequence or that are only partially complementary to any other sequence. For example, the two chains of a double-stranded oligonucleotide can hybridize in a manner that produces one or more short (e.g., two) nucleotide overhangs at one or both ends of the duplex. As another example, a non-specific nucleic acid sequence is a sequence of nucleic acid residues that does not act as an inhibitory nucleic acid when in contact with a cell or organism.

[0194] As used herein, the term "double-stranded oligonucleotide" refers to an oligonucleotide whose core base sequence has enough complementarity to form a duplex structure. A double-stranded oligonucleotide can include a structure formed by annealing a first oligonucleotide to a second complementary oligonucleotide. Double-stranded oligonucleotides can be completely complementary to each other in length with respect to two oligonucleotides. Alternatively, a double-stranded oligonucleotide can have short nucleotide overhangs at one or both ends of the duplex structure. Such double-stranded oligonucleotides include siRNA and microRNA mimics. Double-stranded oligonucleotides can also include single oligonucleotides with sufficient length and self-complementarity to form a duplex structure. Such double-stranded oligonucleotides include stem-loop structures. Double-stranded oligonucleotides can include one or more modifications connected relative to naturally occurring ends, sugars, core bases and / or internucleosides.

[0195] As used herein, the term "modified double-stranded oligonucleotide" refers to a double-stranded oligonucleotide that includes one or more modifications relative to naturally occurring termini, sugars, nucleobases, and / or internucleoside linkages. Where a double-stranded oligonucleotide comprises two separate complementary oligonucleotides, one or both strands may include one or more modifications relative to naturally occurring termini, sugars, nucleobases, and / or internucleoside linkages.

[0196] The terms "small interfering RNA," "short interfering RNA," "silencing RNA," and "siRNA" are used interchangeably herein to refer to a class of double-stranded oligonucleotides that interfere with the expression of a specific gene by promoting mRNA degradation before translation (i.e., through the RNA interference pathway). siRNA includes a guide strand that is complementary to the target mRNA and is integrated into the RNA-induced silencing complex (RISC); and a passenger strand that is complementary to the guide strand and is typically degraded. Typically, siRNA molecules are about 15-50 nucleotides in length, and more typically, 20-30 base nucleotides in length, 20-25 nucleotides in length, or 24-29 nucleotides in length. In an embodiment, siRNA is about 18-25 nucleotides in length. siRNA may include one or more modifications relative to naturally occurring ends, sugars, nucleobases, and / or internucleoside linkages.

[0197] As used herein, the term "microRNA mimics" refers to a synthetic form of a naturally occurring microRNA. A microRNA mimic includes a guide strand that is complementary to one or more target mRNAs and a passenger strand that is complementary to the guide strand. In naturally occurring microRNAs, the guide strand is typically only partially complementary to its target mRNA, and the passenger strand is only partially complementary to the guide strand. A microRNA mimic can include a core base sequence that has 100% identity to a naturally occurring microRNA, or can include a core base sequence that has less than 100% identity to a naturally occurring microRNA. For example, a microRNA mimic can include a passenger strand that is 100% complementary to a guide strand. A microRNA mimic can include one or more modifications relative to naturally occurring ends, sugars, core bases, and / or internucleoside linkages.

[0198] As used herein, the term "single-stranded oligonucleotide" refers to an oligonucleotide that is not hybridized to a complementary strand. A single-stranded oligonucleotide may comprise one or more modifications relative to naturally occurring ends, sugars, nucleobases, and / or internucleoside linkages. Single-stranded oligonucleotides include antisense oligonucleotides. Single-stranded oligonucleotides also include aptamers, which are single-stranded oligonucleotides that fold into a well-defined secondary structure.

[0199] As used herein, the term "modified single-stranded oligonucleotide" refers to a single-stranded oligonucleotide that does not hybridize to a complementary strand and includes one or more modifications relative to naturally occurring termini, sugars, nucleobases, and / or internucleoside linkages. Modified single-stranded oligonucleotides include modified antisense oligonucleotides and aptamers.

[0200] As mentioned herein, " antisense oligonucleotide " is such single-stranded oligonucleotide, it is complementary to at least a portion of a specific target nucleic acid, and therefore can selectively hybridize to at least a portion of a specific target nucleic acid, and can also reduce the transcription of target nucleic acid (for example, mRNA from DNA), reduce the translation of target nucleic acid (for example, mRNA), change transcriptional splicing, or otherwise interfere with the endogenous activity of target nucleic acid. Typically, the length of antisense oligonucleotide is between 15 and 25 bases. Antisense oligonucleotide can include one or more modifications to naturally occurring ends, sugars, core bases and / or internucleoside connections. Antisense oligonucleotides include but are not limited to anti-microRNA oligonucleotides (oligonucleotides complementary to microRNA), steric blocking oligonucleotides (oligonucleotides that interfere with target RNA activity without degrading target RNA) and RNase H oligonucleotides (chemically modified to trigger RNase H-mediated target RNA degradation oligonucleotides).

[0201] A nucleic acid, oligonucleotide, or polynucleotide is "modified" if one or more of the termini, phosphodiester bonds, sugars, or bases are altered from their native form (e.g., from the common form of DNA or RNA to form a nucleotide analog). For example, a nucleic acid is modified if one or more phosphodiester bonds of the nucleic acid are replaced by a phosphoramidate, phosphorothioate, phosphorodithioate, borophosphonate, or O-methylphosphoramidite (see, e.g., Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press). Modified nucleic acids, oligonucleotides, and polynucleotides include those with positive backbones; nonionic backbones and non-ribose backbones, such as those described in U.S. Patents 5,235,033 and 5,034,506 and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & Cook, eds. Modified nucleic acids, oligonucleotides and polynucleotides also include nucleic acids, oligonucleotides and polynucleotides in which one or more residues contain chemically altered ribose, such as 2'-O-methyl-ribose, 2'-deoxy-2'-fluoro-ribose and the ribose "locked" by the covalent bond between 2' and 4' carbons." Bicyclic nucleic acids "or " BNA " residues include a covalent bond between the 2' hydroxyl group of the sugar ring and the 4' carbon of the sugar ring, which essentially "locks" the structure into a rigid conformation. Bicyclic nucleic acid residues comprising a methyleneoxy (4'-CH2-O-2') bridge between the 2' hydroxyl group and the 4' carbon of the ribose are "locked nucleic acids" or "LNAs." Bicyclic nucleic acid residues comprising a 4'-CH(CH3)-O-2' bridge are "restricted ethyl" or "cEt" residues. "Unlocked nucleic acids" or "UNA" residues are acyclic nucleoside derivatives lacking a key between the 2' carbon and the 3' carbon of the sugar ring. In addition, modified nucleic acids, oligonucleotides, and polynucleotides can be modified at one or both of the 5' and 3' ends. For example, an oligonucleotide can include a 5'-(E)-vinylphosphonate group at its terminus. Nucleic acid modifications can be performed for a variety of reasons, for example, to increase the stability and half-life of such molecules in physiological environments, or to prevent immunostimulation.

[0202] In embodiments, the oligonucleotide may consist of, consist essentially of, or comprise a single-stranded locked nucleic acid (LNA) or a modification thereof. In embodiments, the oligonucleotide may consist of, consist essentially of, or comprise a single-stranded phosphorodiamidate morpholino oligomer (PMO) or a modification thereof. In an embodiment, the oligonucleotide may comprise at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, , 97%, 98% or 99% DNA, siRNA, mRNA, locked nucleic acid (LNA), bicyclic nucleic acid (BNA) or phosphorodiamidate morpholino oligomer (PMO) or its modification, etc., or the oligonucleotide may include a certain amount of DNA, siRNA, mRNA, locked nucleic acid (LNA), bicyclic nucleic acid (BNA) or phosphorodiamidate morpholino oligomer (PMO) or its modification, etc., and the amount is within the range defined by any two of the aforementioned values. In an embodiment, the oligonucleotide may include at least 1% and less than 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5% or 4% 2'-O-methoxyethyl / phosphorothioate (MOE).

[0203] As used herein, the term "complement" refers to a nucleotide (e.g., RNA or DNA) or a nucleotide sequence that can base pair with a complementary nucleotide or a sequence of nucleotides. As described herein and well known in the art, the complementary (matching) nucleotide of adenosine is thymidine, and the complementary (matching) nucleotide of guanosine is cytosine. Therefore, the complement can include a nucleotide sequence that base pairs with the corresponding complementary nucleotides of the second nucleic acid sequence. The nucleotides of the complement can partially or completely match the nucleotides of the second nucleic acid sequence. When the nucleotides of the complement fully match each nucleotide of the second nucleic acid sequence, the complement forms a base pair with each nucleotide of the second nucleic acid sequence. When the nucleotides of the complement partially match the nucleotides of the second nucleic acid sequence, only some nucleotides of the complement form base pairs with the nucleotides of the second nucleic acid sequence. Examples of complementary sequences include coding sequences and non-coding sequences, wherein the non-coding sequence contains nucleotides that are complementary to the coding sequence, and thereby forms the complement of the coding sequence. Further examples of complementary sequences are sense sequences and antisense sequences, wherein the sense sequence contains nucleotides that are complementary to the antisense sequence, and thereby forms the complement of the antisense sequence.

[0204] As described herein, sequence complementarity can be partial, in which only some of the nucleic acids match according to base pairing, or complete, in which all nucleic acids match according to base pairing. Thus, two sequences that are complementary to each other can have a specific percentage of nucleotides that participate in nucleobase pairing (i.e., about 60% complementarity over a specific region, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more complementarity).

[0205] "Hybridization" shall mean that a single-stranded nucleic acid (such as a primer) is annealed to another nucleic acid according to the well-known principle of sequence complementarity. In one embodiment, the other nucleic acid is a single-stranded nucleic acid. The tendency of hybridization between nucleic acids depends on the temperature and ionic strength of their environment, the length of the nucleic acids, and the degree of complementarity. The influence of these parameters on hybridization is described in, for example, Sambrook J, Fritsch EF, Maniatis T., molecular cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, New York (1989). As used herein, hybridization of a primer or DNA extension product can be extended by forming a phosphodiester bond with an available nucleotide or nucleotide analog that can form a phosphodiester bond therewith.

[0206] A specific nucleic acid sequence also includes a "splice variant". Similarly, a specific protein encoded by a nucleic acid includes any protein encoded by a splice variant of the nucleic acid. A "splice variant" is a product of alternative splicing of a gene. After transcription, the initial nucleic acid transcript can be spliced ​​so that different (alternative) nucleic acid splicing products encode different polypeptides. The mechanisms of production of splice variants vary, but include alternative splicing of exons. Alternative polypeptides derived from the same nucleic acid by read-through transcription are also included in this definition. Any product of the splicing reaction (including recombinant forms of the splicing products) is included in this definition. Examples of potassium channel splice variants are discussed in Leicher, et al., J. Biol. Chem. 273 (52): 35095-35101 (1998).

[0207] In the context of two or more nucleic acid or polypeptide sequences, the terms "same" or "percent identity" mean that two or more sequences or subsequences are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., at least 60% identity, or at least 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137 %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or in the range limited by any two values ​​above, when comparing and comparing for maximum correspondence on a comparison window or a specified region (identity on a specified region), as measured using BLAST or BLAST2.0 sequence comparison algorithms with default parameters described below or by manual alignment and visual inspection (see, for example, NCBI website etc.). This definition also refers to or can be applied to the complement of a test sequence. This definition also comprises sequences with disappearance and / or interpolation, and sequences with substitutions. As described below, preferred algorithms can resolve gaps, insertions etc. The comparison for determining the purpose of sequence identity percentage can be realized in the various ways belonging to this area of ​​technology, for example, using publicly available computer software, such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Appropriate parameters for measuring alignment (including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared) can be determined by known methods.

[0208] For sequence comparison, usually a sequence serves as a reference sequence, and a test sequence is compared thereto. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, and subsequence coordinates are specified if necessary, and sequence algorithm program parameters are specified. Preferably, default program parameters can be used. Then, the sequence comparison algorithm calculates the sequence identity percentage of the test sequence relative to the reference sequence according to the program parameters.

[0209] As used herein, a "comparison window" includes reference to a segment of any one of a plurality of contiguous positions selected from the group consisting of 10 to 600, typically about 50 to about 200, more typically about 100 to about 150, wherein a sequence can be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be performed by, for example, the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. mol. Biol. 48:443 (1970), by the search similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in molecular Biology (Ausubel et al., eds. 1995 supplement)).

[0210] Compounds and methods

[0211] In one aspect, in particular a compound or lipid-modified oligonucleotide compound has the structure:

[0212]

[0213] A is an oligonucleotide, a nucleic acid, a polynucleotide, a nucleotide or an analog thereof, or a nucleoside or an analog thereof. In embodiments, A is an oligonucleotide. In embodiments, A is a nucleic acid. In embodiments, A is a polynucleotide. In embodiments, A is a nucleotide or an analog thereof. In embodiments, A is a nucleoside or an analog thereof.

[0214] L 3 and L 4and -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO-O-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0215] L 5 Yes-L 5A -L 5B -L 5C -L 5D -L 5E -, and L 6 Yes-L 6A -L 6B -L 6C -L 6D -L 6E -.L 5A 、L 5B 、L 5C 、L 5D 、L 5E 、L 6A 、L 6B 、L 6C 、L 6D and L 6E and -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0216] R 1 and R 2 are independently unsubstituted C1-C 25 Alkyl, where R 1 and R 2 At least one of them is unsubstituted C9-C 19 In an embodiment, R 1 and R 2 are independently unsubstituted C1-C 20 Alkyl, where R 1 and R 2 At least one of them is unsubstituted C9-C 19 alkyl.

[0217] R 3is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0218] t is an integer from 1 to 5.

[0219] In an embodiment, t is 1. In an embodiment, t is 2. In an embodiment, t is 3. In an embodiment, t is 4. In an embodiment, t is 5.

[0220] In an embodiment, A is a double-stranded oligonucleotide or a single-stranded oligonucleotide. In an embodiment, A is a double-stranded oligonucleotide. In an embodiment, A is a single-stranded oligonucleotide. In an embodiment, A is a modified oligonucleotide. In an embodiment, A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide. In an embodiment, A is a modified double-stranded oligonucleotide. In an embodiment, A is a modified single-stranded oligonucleotide.

[0221] In an embodiment, A is siRNA, a microRNA mimic, a stem-loop structure, a single-stranded siRNA, an RNase H oligonucleotide, an anti-microRNA oligonucleotide, a steric blocking oligonucleotide, a CRISPR guide RNA, or an aptamer.

[0222] In an embodiment, an L 3 is attached to the 3' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 is attached to the 3' carbon of the double-stranded oligonucleotide. 3 is attached to the 3' carbon of a single-stranded oligonucleotide. 3 is attached to the 3' carbon of the 3' terminal nucleotide of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 is attached to the 3' carbon of the 3' terminal nucleotide of the double-stranded oligonucleotide. 3 Attached to the 3' carbon of the 3' terminal nucleotide of a single-stranded oligonucleotide.

[0223] In an embodiment, an L 3 is attached to the 5' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 is attached to the 5' carbon of the double-stranded oligonucleotide. 3 is attached to the 5' carbon of the single-stranded oligonucleotide. 3is attached to the 5' carbon of the 5' terminal nucleotide of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 is attached to the 5' carbon of the 5' terminal nucleotide of the double-stranded oligonucleotide. 3 Attached to the 5' carbon of the 5' terminal nucleotide of a single-stranded oligonucleotide.

[0224] In an embodiment, an L 3 is attached to the 2' carbon of a nucleotide of a double-stranded oligonucleotide. 3 is attached to the 2' carbon of a nucleotide of a single-stranded oligonucleotide. In embodiments, the 2' carbon is the 2' carbon of an internal nucleotide.

[0225] In an embodiment, an L 3 is linked to a nucleobase of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 is attached to a nucleobase of a double-stranded oligonucleotide. 3 Attached to the nucleobases of a single-stranded oligonucleotide.

[0226] In an embodiment, L 3 and L 4 is independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO2-O-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene. In embodiments, L 3 is independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO2-O-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene. In embodiments, L 4 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO2-O-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.

[0227] In an embodiment, L 3 are independently a bond. In an embodiment, L 3 are independently -NH-. In an embodiment, L 3 is independently -O-. In an embodiment, L 3 In an embodiment, L 3 are independently -C(O)-. In the embodiment, L 3is independently -NHC(O)-. In the embodiment, L 3 are independently -NHC(O)NH-. In the embodiment, L 3 are independently -C(O)O-. In the embodiment, L 3 are independently -OC(O)-. In the embodiment, L 3 are independently -C(O)NH-. In the embodiment, L 3 In an embodiment, L 3 is independently substituted or unsubstituted alkylene. 3 and are independently substituted or unsubstituted heteroalkylene.

[0228] In an embodiment, L 3 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 3 are independently substituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 3 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 3 are independently substituted or unsubstituted C1-C 20 In the embodiment, L 3 are independently substituted C1-C 20 In the embodiment, L 3 are independently unsubstituted C1-C 20 In the embodiment, L 3 are independently substituted or unsubstituted C1-C 12 In the embodiment, L 3 are independently substituted C1-C 12 In the embodiment, L 3 are independently unsubstituted C1-C 12 In the embodiment, L 3 are independently substituted or unsubstituted C1-C8 alkylene. 3 is independently substituted C1-C8 alkylene. 3 is independently unsubstituted C1-C8 alkylene. 3are independently substituted or unsubstituted C1-C6 alkylene. 3 is independently substituted C1-C6 alkylene. 3 is independently unsubstituted C1-C6 alkylene. 3 are independently substituted or unsubstituted C1-C4 alkylene. 3 is independently substituted C1-C4 alkylene. 3 is independently unsubstituted C1-C4 alkylene. 3 L is independently substituted or unsubstituted ethylene. 3 is independently substituted ethylene. 3 is independently unsubstituted ethylene. 3 is independently substituted or unsubstituted methylene. 3 is independently substituted methylene. 3 and independently unsubstituted methylene.

[0229] In an embodiment, L 3 is independently substituted or unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3, or 4-5 members). 3 is independently substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered, or 4 to 5-membered). 3 is independently unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3, or 4-5 membered). 3 is independently a substituted or unsubstituted 2- to 20-membered heteroalkylene. 3 is independently substituted 2 to 20 membered heteroalkylene. 3 is independently an unsubstituted 2 to 20 membered heteroalkylene. 3 is independently a substituted or unsubstituted 2- to 8-membered heteroalkylene. 3 is independently substituted 2 to 8 membered heteroalkylene. 3 is independently an unsubstituted 2 to 8 membered heteroalkylene. 3 is independently a substituted or unsubstituted 2 to 6 membered heteroalkylene. 3 is independently substituted 2 to 6 membered heteroalkylene. 3is independently an unsubstituted 2- to 6-membered heteroalkylene. In an embodiment, L3 is independently a substituted or unsubstituted 4- to 6-membered heteroalkylene. In an embodiment, L 3 is independently substituted 4 to 6 membered heteroalkylene. 3 is independently unsubstituted 4 to 6 membered heteroalkylene. 3 L is independently a substituted or unsubstituted 2- to 3-membered heteroalkylene. In an embodiment, L is independently a substituted 2- to 3-membered heteroalkylene. In an embodiment, L 3 is independently an unsubstituted 2- to 3-membered heteroalkylene. 3 is independently a substituted or unsubstituted 4- to 5-membered heteroalkylene. 3 is independently substituted 4 to 5 membered heteroalkylene. 3 and independently unsubstituted 4- to 5-membered heteroalkylene.

[0230] In an embodiment, L 4 are independently a bond. In an embodiment, L 4 are independently -NH-. In an embodiment, L 4 is independently -O-. In an embodiment, L 4 In an embodiment, L 4 are independently -C(O)-. In the embodiment, L 4 is independently -NHC(O)-. In the embodiment, L 4 are independently -NHC(O)NH-. In the embodiment, L 4 are independently -C(O)O-. In the embodiment, L 4 are independently -OC(O)-. In the embodiment, L 4 are independently -C(O)NH-. In the embodiment, L 4 In an embodiment, L 4 is independently substituted or unsubstituted alkylene. 4 and are independently substituted or unsubstituted heteroalkylene.

[0231] In an embodiment, L 4 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 4 are independently substituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L4 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 4 are independently substituted or unsubstituted C1-C 20 In the embodiment, L 4 are independently substituted C1-C 20 In the embodiment, L 4 are independently unsubstituted C1-C 20 In the embodiment, L 4 are independently substituted or unsubstituted C1-C 12 In the embodiment, L 4 are independently substituted C1-C 12 In the embodiment, L 4 are independently unsubstituted C1-C 12 In the embodiment, L 4 are independently substituted or unsubstituted C1-C8 alkylene. 4 is independently substituted C1-C8 alkylene. 4 is independently unsubstituted C1-C8 alkylene. 4 are independently substituted or unsubstituted C1-C6 alkylene. 4 is independently substituted C1-C6 alkylene. 4 is independently unsubstituted C1-C6 alkylene. 4 are independently substituted or unsubstituted C1-C4 alkylene. 4 is independently substituted C1-C4 alkylene. 4 is independently unsubstituted C1-C4 alkylene. 4 L is independently substituted or unsubstituted ethylene. 4 is independently substituted ethylene. 4 is independently unsubstituted ethylene. 4 is independently substituted or unsubstituted methylene. 4 is independently substituted methylene. 4 and independently unsubstituted methylene.

[0232] In an embodiment, L 4is independently substituted or unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3, or 4-5 members). 4 is independently substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered, or 4 to 5-membered). 4 is independently unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3, or 4-5 membered). 4 is independently a substituted or unsubstituted 2- to 20-membered heteroalkylene. 4 is independently substituted 2 to 20 membered heteroalkylene. 4 is independently an unsubstituted 2 to 20 membered heteroalkylene. 4 is independently a substituted or unsubstituted 2- to 8-membered heteroalkylene. 4 is independently substituted 2 to 8 membered heteroalkylene. 4 is independently an unsubstituted 2 to 8 membered heteroalkylene. 4 is independently a substituted or unsubstituted 2 to 6 membered heteroalkylene. 4 is independently substituted 2 to 6 membered heteroalkylene. 4 is independently unsubstituted 2 to 6 membered heteroalkylene. 4 is independently a substituted or unsubstituted 4- to 6-membered heteroalkylene. 4 is independently substituted 4 to 6 membered heteroalkylene. 4 is independently unsubstituted 4 to 6 membered heteroalkylene. 4 is independently a substituted or unsubstituted 2- to 3-membered heteroalkylene. 4 is independently substituted 2 to 3 membered heteroalkylene. 4 is independently an unsubstituted 2- to 3-membered heteroalkylene. 4 is independently a substituted or unsubstituted 4- to 5-membered heteroalkylene. 4 is independently substituted 4 to 5 membered heteroalkylene. 4 and independently unsubstituted 4- to 5-membered heteroalkylene.

[0233] In an embodiment, L 3 Independently In an embodiment, L 3 In an embodiment, L 3is independently -O-.

[0234] In an embodiment, L 4 are independently substituted or unsubstituted alkylene or substituted or unsubstituted heteroalkylene. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-. In the embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently substituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0235] In an embodiment, L 4 is independently substituted or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 4 is independently substituted heteroalkylene (e.g., 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 membered). In embodiments, L4 is independently oxo-substituted heteroalkylene (e.g., 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 membered). In embodiments, L 4 and independently unsubstituted heteroalkylene (eg, 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 membered).

[0236] In an embodiment, L 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 4 Independently -L 7 -NH-C(O)-; and L 7are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 4 Independently -L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0237] In an embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently substituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently substituted or unsubstituted C1-C 20 In the embodiment, L 7 are independently substituted C1-C 20 In the embodiment, L 7 C1-C 20 In the embodiment, L 7 C1-C 20 In the embodiment, L 7 are independently unsubstituted C1-C 20 In the embodiment, L 7 are independently substituted or unsubstituted C1-C 12 In the embodiment, L 7 are independently substituted C1-C 12 In the embodiment, L 7 C1-C 12 In the embodiment, L 7 C1-C 12In the embodiment, L 7 are independently unsubstituted C1-C 12 In the embodiment, L 7 are independently substituted or unsubstituted C1-C8 alkylene. 7 is independently substituted C1-C8 alkylene. 7 is independently a C1-C8 alkylene group substituted with a hydroxyl group (OH). 7 is independently a C1-C8 alkylene group substituted with hydroxymethyl. 7 is independently unsubstituted C1-C8 alkylene. 7 are independently substituted or unsubstituted C1-C6 alkylene. 7 is independently substituted C1-C6 alkylene. 7 is independently a C1-C6 alkylene group substituted with a hydroxyl group (OH). 7 is independently a C1-C6 alkylene group substituted with hydroxymethyl. 7 is independently unsubstituted C1-C6 alkylene. 7 are independently substituted or unsubstituted C1-C4 alkylene. 7 is independently substituted C1-C4 alkylene. 7 is independently a C1-C4 alkylene group substituted with a hydroxyl group (OH). 7 is independently a C1-C4 alkylene group substituted with hydroxymethyl. 7 is independently unsubstituted C1-C4 alkylene. 7 are independently substituted or unsubstituted C1-C2 alkylene. 7 is independently substituted C1-C2 alkylene. 7 is independently a C1-C2 alkylene group substituted with a hydroxyl group (OH). 7 is independently a hydroxymethyl-substituted C1-C2 alkylene group. 7 and independently unsubstituted C1-C2 alkylene.

[0238] In an embodiment, L 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C1-C8 alkylene. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently substituted C1-C8 alkylene. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently a C1-C8 alkylene group substituted with a hydroxyl group (OH). 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently a C1-C8 alkylene group substituted with hydroxymethyl. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0239] In an embodiment, L 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently substituted or unsubstituted C3-C8 alkylene. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently substituted C3-C8 alkylene. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently a C3-C8 alkylene group substituted with a hydroxyl group (OH). 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L7 is independently a hydroxymethyl-substituted C3-C8 alkylene group. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0240] In an embodiment, L 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted C5-C8 alkylene. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently substituted C5-C8 alkylene. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently a C5-C8 alkylene group substituted with a hydroxyl group (OH). 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently a hydroxymethyl-substituted C5-C8 alkylene group. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0241] In an embodiment, L 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently substituted or unsubstituted octenyl. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently substituted octenyl. 4 Independently -L 7 -NH-C(O)- or -L 7-C(O)-NH-; and L 7 is independently an octenyl group substituted with a hydroxyl group (OH). 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently unsubstituted octenyl. 4 Independently -L 7 -NH-C(O)-, and L 7 is independently an octenyl group substituted with a hydroxyl group (OH). 4 Independently -L 7 -NH-C(O)-, and L 7 is independently hydroxymethyl substituted octenyl. 4 Independently -L 7 -NH-C(O)-, and L 7 is independently unsubstituted octenyl.

[0242] In an embodiment, L 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently substituted or unsubstituted heptenyl. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently substituted heptenyl. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently a heptenyl group substituted with hydroxyl (OH). 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently unsubstituted heptenyl. 4 Independently -L 7 -NH-C(O)-, and L 7 is independently a heptenyl group substituted with hydroxyl (OH). 4 Independently -L 7 -NH-C(O)-, and L 7 is independently a hydroxymethyl-substituted heptenyl.4 Independently -L 7 -NH-C(O)-, and L 7 is independently unsubstituted heptenyl.

[0243] In an embodiment, L 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 L is independently substituted or unsubstituted hexamethylene. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently substituted hexamethylene. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently a hexamethylene group substituted with a hydroxyl group (OH). 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 L is independently unsubstituted hexamethylene. 4 Independently -L 7 -NH-C(O)-, and L 7 is independently a hexamethylene group substituted with a hydroxyl group (OH). 4 Independently -L 7 -NH-C(O)-, and L 7 is independently a hydroxymethyl substituted hexamethylene. 4 Independently -L 7 -NH-C(O)-, and L 7 and independently unsubstituted hexamethylene.

[0244] In an embodiment, L 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently substituted or unsubstituted pentadiene. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently a substituted pentadiene. In an embodiment, L 4Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently a hydroxy (OH) substituted pentadiene. 4 Independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-; and L 7 is independently unsubstituted pentadiene. 4 Independently -L 7 -NH-C(O)-, and L 7 is independently a hydroxy (OH) substituted pentadiene. 4 Independently -L 7 -NH-C(O)-, and L 7 is independently a hydroxymethyl-substituted pentadiene. 4 Independently -L 7 -NH-C(O)-, and L 7 is independently an unsubstituted pentadiene.

[0245] In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently

[0246] In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently In an embodiment, L 4 Independently

[0247] In an embodiment, -L 3 -L 4 -Independently -L7 -NH-C(O)- or -L 7 -C(O)-NH-. In the embodiment, L 7 is independently substituted or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently oxo-substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently substituted or unsubstituted heteroalkenylene (e.g., 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 members). 7 is independently substituted heteroalkenylene (e.g., 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 members). 7 is independently oxo-substituted heteroalkenylene (e.g., 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 members). 7 is independently unsubstituted heteroalkenylene (e.g., 2-20 membered, 2-12 membered, 2-10 membered, 2-8 membered, 2-6 membered, or 2-4 membered).

[0248] In an embodiment, L 7 is independently a substituted or unsubstituted 2- to 20-membered heteroalkylene. 7 is independently substituted 2 to 20 membered heteroalkylene. 7 is independently oxo-substituted 2 to 20 membered heteroalkylene. 7 is independently an unsubstituted 2 to 20 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2- to 12-membered heteroalkylene. 7 is independently substituted 2 to 12 membered heteroalkylene. 7 is independently oxo-substituted 2 to 12 membered heteroalkylene. 7 is independently an unsubstituted 2 to 12 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2- to 10-membered heteroalkylene.7 is independently substituted 2 to 10 membered heteroalkylene. 7 is independently oxo-substituted 2 to 10 membered heteroalkylene. 7 is independently an unsubstituted 2 to 10 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2- to 8-membered heteroalkylene. 7 is independently substituted 2 to 8 membered heteroalkylene. 7 is independently oxo-substituted 2 to 8 membered heteroalkylene. 7 is independently an unsubstituted 2 to 8 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2 to 6 membered heteroalkylene. 7 is independently substituted 2 to 6 membered heteroalkylene. 7 is independently oxo-substituted 2 to 6 membered heteroalkylene. 7 is independently unsubstituted 2 to 6 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2 to 4 membered heteroalkylene. 7 is independently substituted 2 to 4 membered heteroalkylene. 7 is independently oxo-substituted 2 to 4 membered heteroalkylene. 7 and independently unsubstituted 2- to 4-membered heteroalkylene.

[0249] In an embodiment, L 7 is independently a substituted or unsubstituted 2- to 20-membered heteroalkenylene. 7 is independently substituted 2 to 20 membered heteroalkenylene. 7 is independently oxo-substituted 2 to 20-membered heteroalkenyl. 7 is independently an unsubstituted 2- to 20-membered heteroalkenylene. 7 is independently a substituted or unsubstituted 2- to 12-membered heteroalkenylene. 7 is independently substituted 2 to 12 membered heteroalkenylene. 7 is independently 2 to 12 membered heteroalkenyl substituted with oxo. 7 is independently unsubstituted 2 to 12 membered heteroalkenylene. 7 is independently a substituted or unsubstituted 2- to 10-membered heteroalkenylene. 7 is independently substituted 2 to 10 membered heteroalkenylene. 7is independently 2 to 10 membered heteroalkenyl substituted with oxo. 7 is independently unsubstituted 2 to 10 membered heteroalkenylene. 7 is independently a substituted or unsubstituted 2- to 8-membered heteroalkenylene. 7 is independently substituted 2 to 8 membered heteroalkenylene. 7 is independently 2 to 8 membered heteroalkenyl substituted with oxo. 7 is independently unsubstituted 2 to 8 membered heteroalkenylene. 7 is independently a substituted or unsubstituted 2- to 6-membered heteroalkenylene. 7 is independently substituted 2 to 6 membered heteroalkenylene. 7 is independently 2 to 6 membered heteroalkenyl substituted with oxo. 7 is independently unsubstituted 2 to 6 membered heteroalkenylene. 7 is independently a substituted or unsubstituted 2- to 4-membered heteroalkenylene. 7 is independently substituted 2 to 4 membered heteroalkenylene. 7 is independently 2 to 4 membered heteroalkenyl substituted with oxo. 7 and independently unsubstituted 2- to 4-membered heteroalkenylene.

[0250] In an embodiment, -L 3 -L 4 -Independently -OL 7 -NH-C(O)- or -OL 7 -C(O)-NH-. In the embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, -L 3 -L 4 -Independently -OL 7 -NH-C(O)- or -OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, -L 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, -L 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0251] In an embodiment, -L 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 is independently substituted or unsubstituted C1-C8 alkylene. 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 is independently substituted C1-C8 alkylene. 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 is independently a C1-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4 -Independently -OL 7 -C(O)-NH-, and L 7 is independently a C1-C8 alkylene group substituted with hydroxymethyl. 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0252] In an embodiment, -L 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 is independently substituted or unsubstituted C3-C8 alkylene. 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L7 is independently substituted C3-C8 alkylene. 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 is independently a C3-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4 -Independently -OL 7 -C(O)-NH-, and L 7 is independently a hydroxymethyl-substituted C3-C8 alkylene group. 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0253] In an embodiment, -L 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 is independently substituted or unsubstituted C5-C8 alkylene. 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 is independently substituted C5-C8 alkylene. 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 is independently a C5-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4 -Independently -OL 7 -C(O)-NH-, and L 7 is independently a C5-C8 alkylene substituted with hydroxymethyl. 3 -L 4 -Independently -OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0254] In an embodiment, -L 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7is independently substituted or unsubstituted C1-C8 alkylene. 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 is independently substituted C1-C8 alkylene. 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 is independently a C1-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 is independently a C1-C8 alkylene group substituted with hydroxymethyl. 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0255] In an embodiment, -L 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 is independently substituted or unsubstituted C3-C8 alkylene. 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 is independently substituted C3-C8 alkylene. 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 is independently a C3-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 is independently a hydroxymethyl-substituted C3-C8 alkylene group. 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0256] In an embodiment, -L 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 is independently substituted or unsubstituted C5-C8 alkylene. 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 is independently substituted C5-C8 alkylene. 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 is independently a C5-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 is independently a C5-C8 alkylene substituted with hydroxymethyl. 3 -L 4 -Independently -OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0257] In an embodiment, -L 3 -L 4 -Independently In an embodiment, -L 3 -L 4 -Independently In an embodiment, -L 3 -L 4 -Independently In an embodiment, -L 3 -L 4 -Independently

[0258] In an embodiment, -L 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)- or -OPO2-OL 7 -C(O)-NH-. In the embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, -L 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)- or -OPO2-OL 7 -C(O)-NH-; and L 7 is independently substituted or unsubstituted alkylene. 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently substituted or unsubstituted alkylene. 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently substituted or unsubstituted alkylene. 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)- or -OPO2-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, -L 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, -L 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0259] In an embodiment, -L 3 -L 4 -independently -OPO2-OL 7-C(O)-NH-; and L 7 is independently substituted or unsubstituted C1-C8 alkylene. 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently substituted C1-C8 alkylene. 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a C1-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a C1-C8 alkylene group substituted with hydroxymethyl. 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0260] In an embodiment, -L 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently substituted or unsubstituted C3-C8 alkylene. 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently substituted C3-C8 alkylene. 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a C3-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a hydroxymethyl-substituted C3-C8 alkylene group. 3 -L 4 -independently -OPO2-OL 7-C(O)-NH-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0261] In an embodiment, -L 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently substituted or unsubstituted C5-C8 alkylene. 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently substituted C5-C8 alkylene. 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a C5-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 is independently a C5-C8 alkylene substituted with hydroxymethyl. 3 -L 4 -independently -OPO2-OL 7 -C(O)-NH-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0262] In an embodiment, -L 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently substituted or unsubstituted C1-C8 alkylene. 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently substituted C1-C8 alkylene. 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a C1-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4-independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a C1-C8 alkylene group substituted with hydroxymethyl. 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C1-C8 alkylene.

[0263] In an embodiment, -L 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently substituted or unsubstituted C3-C8 alkylene. 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently substituted C3-C8 alkylene. 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a C3-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a hydroxymethyl-substituted C3-C8 alkylene group. 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C3-C8 alkylene.

[0264] In an embodiment, -L 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently substituted or unsubstituted C5-C8 alkylene. 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently substituted C5-C8 alkylene.3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a C5-C8 alkylene group substituted with a hydroxyl group (OH). 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 is independently a C5-C8 alkylene substituted with hydroxymethyl. 3 -L 4 -independently -OPO2-OL 7 -NH-C(O)-; and L 7 and independently unsubstituted C5-C8 alkylene.

[0265] In an embodiment, -L 3 -L 4 -Independently In an embodiment, -L 3 -L 4 -Independently and is attached to the 3' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is attached to the 5' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is attached to the 2' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is linked to a nucleobase of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is attached to the 3' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is attached to the 5' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is attached to the 2' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4-Independently and is linked to a nucleobase of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is attached to the 3' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is attached to the 5' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is attached to the 2' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is linked to a nucleobase of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is attached to the 3' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is attached to the 5' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is attached to the 2' carbon of a double-stranded oligonucleotide or a single-stranded oligonucleotide. 3 -L 4 -Independently and is linked to the nucleobases of a double-stranded oligonucleotide or a single-stranded oligonucleotide.

[0266] In an embodiment, R 3 and -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, R 3 are independently hydrogen. In an embodiment, R 3 is independently -NH2. In an embodiment, R 3 In an embodiment, R 3 In an embodiment, R 3is independently -C(O)H. In an embodiment, R 3 is independently -C(O)NH2. In an embodiment, R 3 is independently -NHC(O)H. In an embodiment, R 3 is independently -NHC(O)OH. In an embodiment, R 3 is independently -NHC(O)NH2. In an embodiment, R 3 is independently -C(O)OH. In an embodiment, R 3 is independently -OC(O)H. In an embodiment, R 3 is independently -N3.

[0267] In an embodiment, R 3 are independently substituted or unsubstituted alkyl (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 3 are independently substituted or unsubstituted C1-C 20 In an embodiment, R 3 are independently substituted C1-C 20 In an embodiment, R 3 are independently unsubstituted C1-C 20 In an embodiment, R 3 are independently substituted or unsubstituted C1-C 12 In an embodiment, R 3 are independently substituted C1-C 12 In an embodiment, R 3 are independently unsubstituted C1-C 12 In an embodiment, R 3 are independently substituted or unsubstituted C1-C8 alkyl. 3 is independently substituted C1-C8 alkyl. 3 is independently unsubstituted C1-C8 alkyl. 3 are independently substituted or unsubstituted C1-C6 alkyl. 3 is independently substituted C1-C6 alkyl. 3 is independently unsubstituted C1-C6 alkyl. 3 are independently substituted or unsubstituted C1-C4 alkyl. 3 is independently substituted C1-C4 alkyl. 3 is independently unsubstituted C1-C4 alkyl.3 is independently substituted or unsubstituted ethyl. 3 is independently substituted ethyl. 3 is independently unsubstituted ethyl. 3 is independently substituted or unsubstituted methyl. 3 is independently substituted methyl. 3 is independently unsubstituted methyl.

[0268] In an embodiment, L 6 is independently -NHC(O)-. In the embodiment, L 6 are independently -C(O)NH-. In the embodiment, L 6 is independently substituted or unsubstituted alkylene. 6 and are independently substituted or unsubstituted heteroalkylene.

[0269] In an embodiment, L 6 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 6 are independently substituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 6 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 6 are independently substituted or unsubstituted C1-C 20 In the embodiment, L 6 are independently substituted C1-C 20 In the embodiment, L 6 are independently unsubstituted C1-C 20 In the embodiment, L 6 are independently substituted or unsubstituted C1-C 12 In the embodiment, L 6 are independently substituted C1-C 12 In the embodiment, L 6 are independently unsubstituted C1-C 12 In the embodiment, L 6are independently substituted or unsubstituted C1-C8 alkylene. 6 is independently substituted C1-C8 alkylene. 6 is independently unsubstituted C1-C8 alkylene. 6 are independently substituted or unsubstituted C1-C6 alkylene. 6 is independently substituted C1-C6 alkylene. 6 is independently unsubstituted C1-C6 alkylene. 6 are independently substituted or unsubstituted C1-C4 alkylene. 6 is independently substituted C1-C4 alkylene. 6 is independently unsubstituted C1-C4 alkylene. 6 L is independently substituted or unsubstituted ethylene. 6 is independently substituted ethylene. 6 is independently unsubstituted ethylene. 6 is independently substituted or unsubstituted methylene. 6 is independently substituted methylene. 6 and independently unsubstituted methylene.

[0270] In an embodiment, L 6 is independently substituted or unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3, or 4-5 members). 6 is independently substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered, or 4 to 5-membered). 6 is independently unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3, or 4-5 membered). 6 is independently a substituted or unsubstituted 2- to 20-membered heteroalkylene. 6 is independently substituted 2 to 20 membered heteroalkylene. 6 is independently an unsubstituted 2 to 20 membered heteroalkylene. 6 is independently a substituted or unsubstituted 2- to 8-membered heteroalkylene. 6 is independently substituted 2 to 8 membered heteroalkylene. 6 is independently an unsubstituted 2 to 8 membered heteroalkylene.6 is independently a substituted or unsubstituted 2 to 6 membered heteroalkylene. 6 is independently substituted 2 to 6 membered heteroalkylene. 6 is independently unsubstituted 2 to 6 membered heteroalkylene. 6 is independently a substituted or unsubstituted 4- to 6-membered heteroalkylene. 6 is independently substituted 4 to 6 membered heteroalkylene. 6 is independently unsubstituted 4 to 6 membered heteroalkylene. 6 is independently a substituted or unsubstituted 2- to 3-membered heteroalkylene. 6 is independently substituted 2 to 3 membered heteroalkylene. 6 is independently an unsubstituted 2- to 3-membered heteroalkylene. 6 is independently a substituted or unsubstituted 4- to 5-membered heteroalkylene. 6 is independently substituted 4 to 5 membered heteroalkylene. 6 and independently unsubstituted 4- to 5-membered heteroalkylene.

[0271] In an embodiment, L 6A L is independently a bond or unsubstituted alkylene; 6B are independently a bond, -NHC(O)- or unsubstituted arylene; L 6C L is independently a bond, unsubstituted alkylene or unsubstituted arylene; 6D are independently a bond or unsubstituted alkylene; and L 6E is independently a bond or -NHC(O)-. In an embodiment, L 6A is independently a bond or an unsubstituted alkylene. 6B is independently a bond, -NHC(O)- or an unsubstituted arylene group. 6C L is independently a bond, an unsubstituted alkylene group or an unsubstituted arylene group. 6D is independently a bond or an unsubstituted alkylene. 6E is independently a bond or -NHC(O)-.

[0272] In an embodiment, L 6A are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 6A are independently unsubstituted C1-C 20In the embodiment, L 6A are independently unsubstituted C1-C 12 In the embodiment, L 6A is independently unsubstituted C1-C8 alkylene. 6A is independently unsubstituted C1-C6 alkylene. 6A is independently unsubstituted C1-C4 alkylene. 6A is independently unsubstituted ethylene. 6A is independently unsubstituted methylene. 6A Independently a key.

[0273] In an embodiment, L 6B are independently a bond. In an embodiment, L 6B is independently -NHC(O)-. In the embodiment, L 6B are independently unsubstituted arylene groups (e.g., C6-C 12 、C6-C 10 or phenyl). In an embodiment, L 6B are independently unsubstituted C6-C 12 In the embodiment, L 6B are independently unsubstituted C6-C 10 In the embodiment, L 6B is independently unsubstituted phenylene. 6B and independently unsubstituted naphthylene.

[0274] In an embodiment, L 6C are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 6C are independently unsubstituted C1-C 20 In the embodiment, L 6C are independently unsubstituted C1-C 12 In the embodiment, L 6C are independently unsubstituted C1-C8 alkylene. 6C is independently unsubstituted C2-C8 alkynylene. 6C are independently unsubstituted C 1- C6 alkylene. In the embodiment, L 6C is independently unsubstituted C1-C4 alkylene. 6C is independently unsubstituted ethylene. 6Cis independently unsubstituted methylene. 6C are independently a bond or an unsubstituted alkynylene group (e.g., C2-C 20 、C2-C 12 , C2-C8, C2-C6, C2-C4 or C2-C2). In an embodiment, L 6C are independently unsubstituted C2-C 20 In an embodiment, L 6C are independently unsubstituted C2-C 12 In an embodiment, L 6C is independently unsubstituted C2-C8 alkynylene. 6C is independently unsubstituted C2-C6 alkynylene. 6C is independently unsubstituted C2-C4 alkynylene. 6C is independently unsubstituted ethynyl. 6C are independently unsubstituted arylene groups (e.g., C6-C 12 、C6-C 10 or phenyl). In an embodiment, L 6C are independently unsubstituted C6-C 12 In the embodiment, L 6C are independently unsubstituted C6-C 10 In the embodiment, L 6C is independently unsubstituted phenylene. 6C L is independently unsubstituted naphthylene. 6C Independently a key.

[0275] In an embodiment, L 6D are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 6D are independently unsubstituted C1-C 20 In the embodiment, L 6D are independently unsubstituted C1-C 12 In the embodiment, L 6A is independently unsubstituted C1-C8 alkylene. 6D is independently unsubstituted C1-C6 alkylene. 6D is independently unsubstituted C1-C4 alkylene. 6D is independently unsubstituted ethylene. 6Dis independently unsubstituted methylene. 6D Independently a key.

[0276] In an embodiment, L 6E are independently a bond. In an embodiment, L 6E are independently -NHC(O)-.

[0277] In an embodiment, L 6A is independently a bond or an unsubstituted C1-C8 alkylene. 6B is independently a bond, -NHC(O)- or unsubstituted phenylene. 6C L is independently a bond, an unsubstituted C2-C8 alkynylene or an unsubstituted phenylene. 6D is independently a bond or an unsubstituted C1-C8 alkylene. 6E is independently a bond or -NHC(O)-.

[0278] In an embodiment, L 6 Independently key, In an embodiment, L 6 are independently a bond. In an embodiment, L 6 Independently In an embodiment, L 6 Independently In an embodiment, L 6 Independently In an embodiment, L 6 Independently In an embodiment, L 6 Independently

[0279] In an embodiment, L 5 is independently -NHC(O)-. In the embodiment, L 5 are independently -C(O)NH-. In the embodiment, L 5 is independently substituted or unsubstituted alkylene. 5 and are independently substituted or unsubstituted heteroalkylene.

[0280] In an embodiment, L 5 are independently substituted or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5 are independently substituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5 are independently substituted or unsubstituted C1-C 20 In the embodiment, L 5 are independently substituted C1-C 20 In the embodiment, L 5 are independently unsubstituted C1-C 20 In the embodiment, L 5 are independently substituted or unsubstituted C1-C 12 In the embodiment, L 5 are independently substituted C1-C 12 In the embodiment, L 5 are independently unsubstituted C1-C 12 In the embodiment, L 5 are independently substituted or unsubstituted C1-C8 alkylene. 5 is independently substituted C1-C8 alkylene. 5 is independently unsubstituted C1-C8 alkylene. 5 are independently substituted or unsubstituted C1-C6 alkylene. 5 is independently substituted C1-C6 alkylene. 5 is independently unsubstituted C1-C6 alkylene. 5 are independently substituted or unsubstituted C1-C4 alkylene. 5 is independently substituted C1-C4 alkylene. 5 is independently unsubstituted C1-C4 alkylene. 5 L is independently substituted or unsubstituted ethylene. 5 is independently substituted ethylene. 5 is independently unsubstituted ethylene. 5 is independently substituted or unsubstituted methylene. 5 is independently substituted methylene. 5 and independently unsubstituted methylene.

[0281] In an embodiment, L 5is independently substituted or unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3, or 4-5 members). 5 is independently substituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered, or 4 to 5-membered). 5 is independently unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3, or 4-5 membered). 5 is independently a substituted or unsubstituted 2- to 20-membered heteroalkylene. 5 is independently substituted 2 to 20 membered heteroalkylene. 5 is independently an unsubstituted 2 to 20 membered heteroalkylene. 5 is independently a substituted or unsubstituted 2- to 8-membered heteroalkylene. 5 is independently substituted 2 to 8 membered heteroalkylene. 5 is independently an unsubstituted 2 to 8 membered heteroalkylene. 5 is independently a substituted or unsubstituted 2 to 6 membered heteroalkylene. 5 is independently substituted 2 to 6 membered heteroalkylene. 5 is independently unsubstituted 2 to 6 membered heteroalkylene. 5 is independently a substituted or unsubstituted 4- to 6-membered heteroalkylene. 5 is independently substituted 4 to 6 membered heteroalkylene. 5 is independently unsubstituted 4 to 6 membered heteroalkylene. 5 is independently a substituted or unsubstituted 2- to 3-membered heteroalkylene. 5 is independently substituted 2 to 3 membered heteroalkylene. 5 is independently an unsubstituted 2- to 3-membered heteroalkylene. 5 is independently a substituted or unsubstituted 4- to 5-membered heteroalkylene. 6 is independently substituted 4 to 5 membered heteroalkylene. 6 and independently unsubstituted 4- to 5-membered heteroalkylene.

[0282] In an embodiment, L 5A L is independently a bond or unsubstituted alkylene; 5B are independently a bond, -NHC(O)- or unsubstituted arylene; L 5CL is independently a bond, unsubstituted alkylene or unsubstituted arylene; 5D are independently a bond or unsubstituted alkylene; and L 5E is independently a bond or -NHC(O)-. In an embodiment, L 5A is independently a bond or an unsubstituted alkylene. 5B is independently a bond, -NHC(O)- or an unsubstituted arylene group. 5C L is independently a bond, an unsubstituted alkylene group or an unsubstituted arylene group. 5D is independently a bond or an unsubstituted alkylene. 5E is independently a bond or -NHC(O)-.

[0283] In an embodiment, L 5A are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5A are independently unsubstituted C1-C 20 In the embodiment, L 5A are independently unsubstituted C1-C 12 In the embodiment, L 5A is independently unsubstituted C1-C8 alkylene. 5A is independently unsubstituted C1-C6 alkylene. 5A is independently unsubstituted C1-C4 alkylene. 5A is independently unsubstituted ethylene. 5A is independently unsubstituted methylene. 5A Independently a key.

[0284] In an embodiment, L 5B are independently a bond. In an embodiment, L 5B is independently -NHC(O)-. In the embodiment, L 5B are independently unsubstituted arylene groups (e.g., C6-C 12 、C6-C 10 or phenyl). In an embodiment, L 5B are independently unsubstituted C6-C 12 In the embodiment, L 5B are independently unsubstituted C6-C 10 In the embodiment, L 5B is independently unsubstituted phenylene. 5Band independently unsubstituted naphthylene.

[0285] In an embodiment, L 5C are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5C are independently unsubstituted C1-C 20 In the embodiment, L 5C are independently unsubstituted C1-C 12 In the embodiment, L 5C are independently unsubstituted C1-C8 alkylene. 5C is independently unsubstituted C2-C8 alkynylene. 5C is independently unsubstituted C1-C6 alkylene. 5C is independently unsubstituted C1-C4 alkylene. 5C is independently unsubstituted ethylene. 5C is independently unsubstituted methylene. 5C are independently a bond or an unsubstituted alkynylene group (e.g., C2-C 20 、C2-C 12 , C2-C8, C2-C6, C2-C4 or C2-C2). In an embodiment, L 5C are independently unsubstituted C2-C 20 In an embodiment, L 5C are independently unsubstituted C2-C 12 In an embodiment, L 5C is independently unsubstituted C2-C8 alkynylene. 5C is independently unsubstituted C2-C6 alkynylene. 5C is independently unsubstituted C2-C4 alkynylene. 5C is independently unsubstituted ethynyl. 5C are independently unsubstituted arylene groups (e.g., C6-C 12 、C6-C 10 or phenyl). In an embodiment, L 5C are independently unsubstituted C6-C 12 In the embodiment, L 5C are independently unsubstituted C6-C 10 In the embodiment, L 5C is independently unsubstituted phenylene.5C L is independently unsubstituted naphthylene. 5C Independently a key.

[0286] In an embodiment, L 5D are independently a bond or an unsubstituted alkylene group (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 5D are independently unsubstituted C1-C 20 In the embodiment, L 5D are independently unsubstituted C1-C 12 In the embodiment, L 5A is independently unsubstituted C1-C8 alkylene. 5D is independently unsubstituted C1-C6 alkylene. 5D is independently unsubstituted C1-C4 alkylene. 5D is independently unsubstituted ethylene. 5D is independently unsubstituted methylene. 5D Independently a key.

[0287] In an embodiment, L 5E are independently a bond. In an embodiment, L 5E are independently -NHC(O)-.

[0288] In an embodiment, L 5A is independently a bond or an unsubstituted C1-C8 alkylene. 5B is independently a bond, -NHC(O)- or unsubstituted phenylene. 5C L is independently a bond, an unsubstituted C2-C8 alkynylene or an unsubstituted phenylene. 5D is independently a bond or an unsubstituted C1-C8 alkylene. 5E is independently a bond or -NHC(O)-.

[0289] In an embodiment, L 5 Independently key, In an embodiment, L 5 are independently a bond. In an embodiment, L 5 Independently In an embodiment, L 5 Independently In an embodiment, L 5 Independently In an embodiment, L 5 Independently In an embodiment, L 5 Independently

[0290] In an embodiment, R 1 is an unsubstituted alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 is an unsubstituted unbranched alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 is an unsubstituted unbranched saturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0291] In an embodiment, R 1 is an unsubstituted C1-C 17 In an embodiment, R 1 is unsubstituted C 11 -C 17 In an embodiment, R 1 is unsubstituted C 13 -C 17 In an embodiment, R 1 is unsubstituted C 15 In an embodiment, R 1 It is an unsubstituted unbranched C1-C 17 In an embodiment, R 1 is an unsubstituted unbranched C 11- C 17 In an embodiment, R 1 is an unsubstituted unbranched C 13 -C 17 In an embodiment, R 1 is an unsubstituted unbranched C 15 In an embodiment, R 1 It is an unsubstituted unbranched saturated C1-C 17 In an embodiment, R 1is an unsubstituted unbranched saturated C 11 -C 17 In an embodiment, R 1 is an unsubstituted unbranched saturated C 13 -C 17 In an embodiment, R 1 is an unsubstituted unbranched saturated C 15 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C1-C 17 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C 11 -C 17 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C 13 -C 17 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C 15 alkyl.

[0292] In an embodiment, R 2 is an unsubstituted alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 is an unsubstituted unbranched alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 is an unsubstituted unbranched saturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 17 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0293] In an embodiment, R 2 is an unsubstituted C1-C 17 In an embodiment, R 2 is unsubstituted C 11 -C 17 In an embodiment, R 2 is unsubstituted C 13 -C 17 In an embodiment, R 2is unsubstituted C 15 In an embodiment, R 2 It is an unsubstituted unbranched C1-C 17 In an embodiment, R 2 is an unsubstituted unbranched C 11 -C 17 In an embodiment, R 2 is an unsubstituted unbranched C 13 -C 17 In an embodiment, R 2 is an unsubstituted unbranched C 15 In an embodiment, R 2 It is an unsubstituted unbranched saturated C1-C 17 In an embodiment, R 2 is an unsubstituted unbranched saturated C 11 -C 17 In an embodiment, R 2 is an unsubstituted unbranched saturated C 13 -C 17 In an embodiment, R 2 is an unsubstituted unbranched saturated C 15 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C1-C 17 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 11 -C 17 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 13 -C 17 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 15 alkyl.

[0294] In an embodiment, R 1 and R 2 At least one of them is unsubstituted C1-C 19 In an embodiment, R 1 and R 2 At least one of them is unsubstituted C9-C 19 In an embodiment, R 1 and R 2 At least one of them is unsubstituted C 11 -C 19 In an embodiment, R 1 and R 2 At least one of them is unsubstituted C 13 -C 19 alkyl.

[0295] In an embodiment, R 1 is an unsubstituted C1-C 19 In an embodiment, R 1 is unsubstituted C9-C 19 In an embodiment, R 1 is unsubstituted C 11 -C 19 In an embodiment, R 1 is unsubstituted C 13 -C 19 In an embodiment, R 1 It is an unsubstituted unbranched C1-C 19 In an embodiment, R 1 It is an unsubstituted unbranched C9-C 19 In an embodiment, R 1 is an unsubstituted unbranched C 11 -C 19 In an embodiment, R 1 is an unsubstituted unbranched C 13 -C 19 In an embodiment, R 1 It is an unsubstituted unbranched saturated C1-C 19 In an embodiment, R 1 It is an unsubstituted unbranched saturated C9-C 19 In an embodiment, R 1 is an unsubstituted unbranched saturated C 11 -C 19 In an embodiment, R 1 is an unsubstituted unbranched saturated C 13 -C 19 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C1-C 19 In an embodiment, R 1 is an unsubstituted unbranched unsaturated C9-C19 alkyl group. 1 It is an unsubstituted unbranched unsaturated C 11 -C 19 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C 13 -C 19 alkyl.

[0296] In an embodiment, R 2 is an unsubstituted C1-C 19 In an embodiment, R 2 is unsubstituted C9-C 19In an embodiment, R 2 is unsubstituted C 11 -C 19 In an embodiment, R 2 is unsubstituted C 13 -C 19 In an embodiment, R 2 It is an unsubstituted unbranched C1-C 19 In an embodiment, R 2 It is an unsubstituted unbranched C9-C 19 In an embodiment, R 2 is an unsubstituted unbranched C 11 -C 19 In an embodiment, R 2 is an unsubstituted unbranched C 13 -C 19 In an embodiment, R 2 It is an unsubstituted unbranched saturated C1-C 19 In an embodiment, R 2 It is an unsubstituted unbranched saturated C9-C 19 In an embodiment, R 2 is an unsubstituted unbranched saturated C 11 -C 19 In an embodiment, R 2 is an unsubstituted unbranched saturated C 13 -C 19 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C1-C 19 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C9-C 19 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 11 -C 19 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C 13 -C 19 alkyl.

[0297] In an embodiment, the oligonucleotide is an antisense oligonucleotide. In an embodiment, the oligonucleotide is an siRNA. In an embodiment, the oligonucleotide is a microRNA mimic. In an embodiment, the oligonucleotide is a stem-loop structure. In an embodiment, the oligonucleotide is a single-stranded siRNA. In an embodiment, the oligonucleotide is an RNase H oligonucleotide. In an embodiment, the oligonucleotide is an anti-microRNA oligonucleotide. In an embodiment, the oligonucleotide is a steric blocking oligonucleotide. In an embodiment, the oligonucleotide is an aptamer. In an embodiment, the oligonucleotide is a CRISPR guide RNA.

[0298] In embodiments, the oligonucleotide is a modified oligonucleotide.

[0299] In embodiments, the oligonucleotide comprises nucleotide analogs.

[0300] In an embodiment, the oligonucleotide comprises locked nucleic acid (LNA) residues, restricted ethyl (cEt) residues, bicyclic nucleic acid (BNA) residues, unlocked nucleic acid (UNA) residues, phosphorodiamidate morpholino oligomers (PMO) monomers, peptide nucleic acid (PNA) monomers, 2'-O-methyl (2'-OMe) residues, 2'-O-methyloxyethyl residues, 2'-deoxy-2'-fluoro residues, 2'-O-methoxyethyl / phosphorothioate residues, phosphoramidate, phosphorodiamidate, phosphorothioate, phosphorodithioate, phosphonocarboxylic acid, phosphonocarboxylate, phosphonoacetic acid, phosphonoformic acid, methylphosphonate, borophosphonate or O-methylphosphoramidite. In an embodiment, the oligonucleotide comprises bicyclic nucleic acid (BNA) residues. In an embodiment, the bicyclic nucleic acid residues are locked nucleic acid (LNA). In an embodiment, the bicyclic nucleic acid (BNA) residues are restricted ethyl (cEt) residues. In an embodiment, the oligonucleotide comprises unlocked nucleic acid (UNA) residues. In an embodiment, the oligonucleotide comprises a phosphorodiamidate morpholino oligomer (PMO) monomer. In an embodiment, the oligonucleotide comprises a peptide nucleic acid (PNA) monomer. In an embodiment, the oligonucleotide comprises a 2'-O-methyl (2'-OMe) residue. In an embodiment, the oligonucleotide comprises a 2'-O-methyloxyethyl residue. In an embodiment, the oligonucleotide comprises a 2'-deoxy-2'-fluoro residue. In an embodiment, the oligonucleotide comprises a 2'-O-methoxyethyl / phosphorothioate residue. In an embodiment, the oligonucleotide comprises a phosphorodiamidate. In an embodiment, the oligonucleotide comprises a phosphorothioate. In an embodiment, the oligonucleotide comprises a phosphorodithioate. In an embodiment, the oligonucleotide comprises a phosphonocarboxylic acid. In an embodiment, the oligonucleotide comprises a phosphonocarboxylate. In an embodiment, the oligonucleotide comprises phosphonoacetic acid. In an embodiment, the oligonucleotide comprises phosphonoformic acid. In an embodiment, the oligonucleotide comprises methylphosphonate. In an embodiment, the oligonucleotide comprises borophosphonate. In an embodiment, the oligonucleotide comprises O-methylphosphoramidite.

[0301] In an embodiment, provided herein are compounds having the structure of Formula I:

[0302]

[0303] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing portion at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide, and X1 is L1 is -(CH2) n -、-(CH2) n L2(CH2) n- or a bond; L2 is -C(=O)NH-, and wherein each m is independently an integer from 10 to 18, and wherein each n is independently an integer from 1 to 6. In an embodiment, X1 is: In an embodiment, X1 is Each m is 10, and n is 3. In an embodiment, X1 is Each m is 11, and n is 3. In an embodiment, X1 is Each m is 12, and n is 3. In an embodiment, X1 is Each m is 13, and n is 3. In an embodiment, X1 is Each m is 14, and n is 3. In an embodiment, X1 is Each m is 15, and n is 3. In an embodiment, X1 is Each m is 16, and n is 3. In an embodiment, X1 is Each m is 17, and n is 3. In an embodiment, X1 is Each m is 18, and n is 3. In an embodiment, X1 is Each m is 10. In the embodiment, X1 is and each m is 11. In an embodiment, X1 is and each m is 12. In an embodiment, X1 is and each m is 13. In an embodiment, X1 is and each m is 14. In an embodiment, X1 is and each m is 15. In an embodiment, X1 is and each m is 16. In an embodiment, X1 is and each m is 17. In an embodiment, X1 is And each m is 18.

[0304] In an embodiment, X1 is L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is 10. In an embodiment, X1 is L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is 11. In an embodiment, X1 is L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is 12. In an embodiment, X1 is L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is 13. In an embodiment, X1 is L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is 14. In an embodiment, X1 is L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is 15. In an embodiment, X1 is L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is 16. In an embodiment, X1 is L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is 17. In an embodiment, X1 is L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is 18.

[0305] In an embodiment, L1 is a bond; and each m is independently an integer from 10 to 16. In an embodiment, L1 is a bond; and each m is independently an integer from 12 to 16. In an embodiment, L1 is a bond; and each m is independently an integer from 12 to 14. In an embodiment, L1 is a bond; and each m is 14. In an embodiment, L1 is -(CH2) n L2(CH2) n -; L2 is -C(=O)NH-; each m is independently an integer from 10 to 16; and each n is independently an integer from 1 to 6. In an embodiment, L1 is -(CH2) n L2(CH2) n -; L2 is -C(=O)NH-; each m is independently an integer from 12 to 16; and each n is independently an integer from 1 to 6. In an embodiment, L1 is -(CH2) n L2(CH2) n -; L2 is -C(=O)NH-; each m is independently an integer from 12 to 14; and each n is independently an integer from 1 to 6. In an embodiment, L1 is -(CH2) n L2(CH2) n -; L2 is -C(=O)NH-; each m is independently 14; and each n is independently an integer from 1 to 6. In an embodiment, L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is independently an integer from 10 to 16. In an embodiment, L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is independently an integer from 12 to 16. In an embodiment, L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is independently an integer from 12 to 14. In an embodiment, L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is independently an integer from 12 to 14. In an embodiment, L1 is -(CH2)3C(=O)NH(CH2)5-; and each m is 14. In an embodiment, each m is 14.

[0306] In an embodiment, provided herein are compounds having the structure of Formula Ia:

[0307]

[0308] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide, and wherein m is an integer from 10 to 18.

[0309]

[0310] The moiety of Formula Ia above represented is the lipid-containing moiety of Formula Ia.

[0311] In an embodiment, provided herein are compounds having the structure of Formula Ib:

[0312] cet

[0313] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide, and wherein m is an integer from 10 to 18.

[0314]

[0315] The moiety of Formula Ib above represented is the lipid-containing moiety of Formula Ib.

[0316] In embodiments of compounds having a structure of Formula I, Ia, or Ib, each m is an integer from 12 to 16. In embodiments, each m is an integer from 12 to 14. In embodiments, each m is 10, L1 is -(CH2) n -, and n is 3. In an embodiment, each m is 11, L1 is -(CH2) n -, and n is 3. In an embodiment, each m is 12, L1 is -(CH2) n -, and n is 3. In an embodiment, each m is 13, L1 is -(CH2) n -, and n is 3. In an embodiment, each m is 14, L1 is -(CH2) n -, and n is 3. In an embodiment, each m is 15, L1 is -(CH2) n -, and n is 3. In an embodiment, each m is 16, L1 is -(CH2) n -, and n is 3. In an embodiment, each m is 17, L1 is -(CH2) n -, and n is 3. In an embodiment, each m is 18, L1 is -(CH2) n-, and n is 3.

[0317] In an embodiment, provided herein are lipid-conjugated compounds having the structure of Formula II:

[0318]

[0319] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide.

[0320]

[0321] The moiety of Formula II above represented is the lipid-containing moiety of Formula II.

[0322] In an embodiment, provided herein are lipid-conjugated compounds having the structure of Formula IIa:

[0323]

[0324] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide.

[0325]

[0326] The moiety of Formula IIa above represented is the lipid-containing moiety of Formula IIa.

[0327] In an embodiment, provided herein are lipid-conjugated compounds having the structure of Formula IIb:

[0328]

[0329] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide.

[0330]

[0331] The moiety of Formula lib above represented is the lipid-containing moiety of Formula lib.

[0332] In an embodiment, provided herein are lipid-conjugated compounds having the structure of Formula III:

[0333]

[0334] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to Z1 at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide, wherein Z1 is wherein p is an integer from 10 to 18, and wherein the modified double-stranded oligonucleotide is conjugated to Z2 at the 5' end of one strand of the modified double-stranded oligonucleotide or the 5' end of the modified single-stranded oligonucleotide, wherein Z2 is wherein q is an integer from 10 to 18. In an embodiment, p is 14; and q is 14.

[0335] In an embodiment, provided herein are lipid-conjugated compounds having the structure of Formula IIIa:

[0336]

[0337] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is bound to a lipid moiety at the 3' end of one chain of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide. Conjugated, and wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or the 5' end of the modified single-stranded oligonucleotide conjugation.

[0338] In an embodiment, provided herein are lipid-conjugated compounds having the structure of Formula IIIb:

[0339]

[0340] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is bound to a lipid moiety at the 3' end of one chain of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide. Conjugated, and wherein the modified double-stranded oligonucleotide or single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or the 5' end of the modified single-stranded oligonucleotide conjugation.

[0341] In embodiments, L1 is a bond, a substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or an unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2) or substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered). In an embodiment, L1 is substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered). 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2) or substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered). In an embodiment, L1 is substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members). In an embodiment, L1 is an unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4 or C1-C2) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members). 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2) or unsubstituted heteroalkylene (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members). In embodiments, when L1 is substituted, L1 is substituted with a substituent group. In embodiments, when L1 is substituted, L1 is substituted with a substituent group of limited size. In embodiments, when L1 is substituted, L1 is substituted with a lower substituent group.

[0342] In an embodiment, L1 is a bond. In an embodiment, L1 is -(CH2) n -or-(CH2) n L2(CH2) n -. In an embodiment, L1 is -(CH2) n -. In an embodiment, L1 is -(CH2) n L2(CH2) n-. In an embodiment, n is 1 to 6. In an embodiment, n is 1 to 5. In an embodiment, n is 1 to 4. In an embodiment, n is 1 to 3. In an embodiment, n is 1 to 2. In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3. In an embodiment, n is 4. In an embodiment, n is 5. In an embodiment, n is 6.

[0343] In an embodiment, each occurrence of n (i.e., n' and n") may be the same or different. In an embodiment, each occurrence of (i.e., n' and n") may be the same. In an embodiment, each occurrence of n (i.e., n' and n") may be different. In an embodiment, n' is 1 to 6. In an embodiment, n' is 1 to 5. In an embodiment, n' is 1 to 4. In an embodiment, n' is 1 to 3. In an embodiment, n' is 1 to 2. In an embodiment, n' is 1. In an embodiment, n' is 2. In an embodiment, n' is 3. In an embodiment, n' is 4. In an embodiment, n' is 5. In an embodiment, n' is 6. In an embodiment, n" is 1 to 6. In an embodiment, n" is 1 to 5. In an embodiment, n" is 1 to 4. In an embodiment, n" is 1 to 3. In an embodiment, n" is 1 to 2. In an embodiment, n" is 1. In an embodiment, n" is 2. In an embodiment, n" is 3. In an embodiment, n" is 4. In an embodiment, n" is 5. In an embodiment, n" is 6.

[0344] In an embodiment, m is from 10 to 18. In an embodiment, m is from 10 to 17. In an embodiment, m is from 10 to 16. In an embodiment, m is from 10 to 15. In an embodiment, m is from 10 to 14. In an embodiment, m is from 10 to 13. In an embodiment, m is from 10 to 12. In an embodiment, m is from 10 to 11. In an embodiment, m is 10. In an embodiment, m is 11. In an embodiment, m is 12. In an embodiment, m is 13. In an embodiment, m is 14. In an embodiment, m is 15. In an embodiment, m is 16. In an embodiment, m is 17. In an embodiment, m is 18.

[0345] In an embodiment, L2 is -C(=O)NH-, -C(=O)O-, -OC(=O)O-, -NHC(=O)O-, -NHC(=O)NH-, -C(=S)NH-, -C(=O)S-, -NH-, O (oxygen) or S (sulfur). In an embodiment, L2 is -C(=O)NH-. In an embodiment, L2 is -C(=O)O-. In an embodiment, L2 is -OC(=O)O-. In an embodiment, L2 is -NHC(=O)O-. In an embodiment, L2 is -NHC(=O)NH-. In an embodiment, L2 is -C(=S)NH-. In an embodiment, L2 is -C(=O)S-. In an embodiment, L2 is -NH-. In an embodiment, L2 is O (oxygen). In an embodiment, L2 is S (sulfur).

[0346] L 3 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO2-O-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 3are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO2-O-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 3 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO2-O-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L3 When replaced, L 3 In an embodiment, when L 3 When replaced, L 3 is substituted with a size-restricted substituent group. In an embodiment, when L 3 When replaced, L 3 Substituted with a lower substituent group.

[0347] L 4 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO2-O-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 4 is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO2-O-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 4 is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO2-O-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 4 When replaced, L 4 In an embodiment, when L 4 When replaced, L 4 is substituted with a size-restricted substituent group. In an embodiment, when L 4 When replaced, L 4 Substituted with a lower substituent group.

[0348] L 5 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 5 When replaced, L 5 In an embodiment, when L 5 When replaced, L 5 is substituted with a size-restricted substituent group. In an embodiment, when L 5 When replaced, L 5 Substituted with a lower substituent group.

[0349] L 5A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 5A When replaced, L 5A In an embodiment, when L 5A When replaced, L 5A is substituted with a size-restricted substituent group. In an embodiment, when L 5A When replaced, L 5A Substituted with a lower substituent group.

[0350] L 5B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 5B When replaced, L 5B In an embodiment, when L 5B When replaced, L 5B is substituted with a size-restricted substituent group. In an embodiment, when L 5B When replaced, L 5B Substituted with a lower substituent group.

[0351] L 5C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 5C When replaced, L 5C In an embodiment, when L 5C When replaced, L 5C is substituted with a size-restricted substituent group. In an embodiment, when L 5C When replaced, L 5C Substituted with a lower substituent group.

[0352] L 5D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 5D When replaced, L 5D In an embodiment, when L 5D When replaced, L 5D is substituted with a size-restricted substituent group. In an embodiment, when L 5D When replaced, L 5D Substituted with a lower substituent group.

[0353] L 5E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 5E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 5E When replaced, L 5E In an embodiment, when L 5E When replaced, L 5E is substituted with a size-restricted substituent group. In an embodiment, when L 5E When replaced, L 5E Substituted with a lower substituent group.

[0354] L 6 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group), or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 6 When replaced, L 6 In an embodiment, when L 6 When replaced, L 6 is substituted with a size-restricted substituent group. In an embodiment, when L 6 When replaced, L 6 Substituted with a lower substituent group.

[0355] L 6A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 6A When replaced, L 6A In an embodiment, when L 6A When replaced, L 6A is substituted with a size-restricted substituent group. In an embodiment, when L 6A When replaced, L 6A Substituted with a lower substituent group.

[0356] L 6B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 6B When replaced, L 6B In an embodiment, when L 6B When replaced, L 6B is substituted with a size-restricted substituent group. In an embodiment, when L 6B When replaced, L 6B Substituted with a lower substituent group.

[0357] L 6C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 6C When replaced, L 6C In an embodiment, when L 6C When replaced, L 6C is substituted with a size-restricted substituent group. In an embodiment, when L 6C When replaced, L 6C Substituted with a lower substituent group.

[0358] L 6D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 6D When replaced, L 6D In an embodiment, when L 6D When replaced, L 6D is substituted with a size-restricted substituent group. In an embodiment, when L 6D When replaced, L 6D Substituted with a lower substituent group.

[0359] L 6E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent group, a substituent group of limited size, or a lower substituent group) alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkylene (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) arylene (e.g., C6-C 12 、C6-C 10or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroarylene (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, L 6E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkylene (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkylene (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroarylene (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when L 6E When replaced, L 6E In an embodiment, when L 6E When replaced, L 6E is substituted with a size-restricted substituent group. In an embodiment, when L 6E When replaced, L 6E Substituted with a lower substituent group.

[0360] In an embodiment, L 7 are independently substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 is independently substituted (eg, substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) alkylene (eg, C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, L 7 are independently unsubstituted alkylene (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2).

[0361] In an embodiment, L 7 is independently substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroalkylene (e.g., 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 membered). In embodiments, L 7 is independently substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently unsubstituted heteroalkylene (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 10-membered, 2 to 8-membered, 2 to 6-membered, or 2 to 4-membered). 7 is independently substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroalkenylene (e.g., 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 membered). In embodiments, L 7 is independently substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroalkenylene (e.g., 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 membered). In embodiments, L 7 is independently unsubstituted heteroalkenylene (e.g., 2-20, 2-12, 2-10, 2-8, 2-6, or 2-4 members). 7 When replaced, L 7 In an embodiment, when L 7 When replaced, L 7 is substituted with a size-restricted substituent group. In an embodiment, when L 7 When replaced, L 7 Substituted with a lower substituent group.

[0362] In an embodiment, R 1 is an unsubstituted alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 is an unsubstituted C1-C 25 In an embodiment, R 1 is an unsubstituted C1-C 20 In an embodiment, R 1 is an unsubstituted C1-C 12In an embodiment, R 1 is an unsubstituted C1-C8 alkyl. 1 is an unsubstituted C1-C6 alkyl. 1 is an unsubstituted C1-C4 alkyl group. 1 It is an unsubstituted C1-C2 alkyl group.

[0363] In an embodiment, R 1 is an unsubstituted branched alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted branched C1-C 25 In an embodiment, R 1 It is an unsubstituted branched C1-C 20 In an embodiment, R 1 It is an unsubstituted branched C1-C 12 In an embodiment, R 1 is an unsubstituted branched C1-C8 alkyl group. 1 is an unsubstituted branched C1-C6 alkyl group. 1 is an unsubstituted branched C1-C4 alkyl group. 1 It is an unsubstituted branched C1-C2 alkyl group.

[0364] In an embodiment, R 1 is an unsubstituted unbranched alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted unbranched C1-C 25 In an embodiment, R 1 It is an unsubstituted unbranched C1-C 20 In an embodiment, R 1 It is an unsubstituted unbranched C1-C 12 In an embodiment, R 1 is an unsubstituted unbranched C1-C8 alkyl group. 1 is an unsubstituted unbranched C1-C6 alkyl group. 1 is an unsubstituted unbranched C1-C4 alkyl group. 1 It is an unsubstituted unbranched C1-C2 alkyl group.

[0365] In an embodiment, R 1 is an unsubstituted branched saturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted branched saturated C1-C 25 In an embodiment, R 1 It is an unsubstituted branched saturated C1-C 20 In an embodiment, R 1 It is an unsubstituted branched saturated C1-C 12 In an embodiment, R 1 is an unsubstituted branched saturated C1-C8 alkyl group. 1 is an unsubstituted branched saturated C1-C6 alkyl group. 1 is an unsubstituted branched saturated C1-C4 alkyl group. 1 It is an unsubstituted branched saturated C1-C2 alkyl group.

[0366] In an embodiment, R 1 is an unsubstituted branched unsaturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted branched unsaturated C1-C 25 In an embodiment, R 1 It is an unsubstituted branched unsaturated C1-C 20 In an embodiment, R 1 It is an unsubstituted branched unsaturated C1-C 12 In an embodiment, R 1 is an unsubstituted branched unsaturated C1-C8 alkyl group. 1 is an unsubstituted branched unsaturated C1-C6 alkyl group. 1 is an unsubstituted branched unsaturated C1-C4 alkyl group. 1 It is an unsubstituted branched saturated C1-C2 alkyl group.

[0367] In an embodiment, R 1 is an unsubstituted unbranched saturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12, C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted unbranched saturated C1-C 25 In an embodiment, R 1 It is an unsubstituted unbranched saturated C1-C 20 In an embodiment, R 1 It is an unsubstituted unbranched saturated C1-C 12 In an embodiment, R 1 is an unsubstituted, unbranched, saturated C1-C8 alkyl group. 1 is an unsubstituted, unbranched, saturated C1-C6 alkyl group. 1 is an unsubstituted, unbranched, saturated C1-C4 alkyl group. 1 It is an unsubstituted unbranched saturated C1-C2 alkyl group.

[0368] In an embodiment, R 1 is an unsubstituted unbranched unsaturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C1-C 25 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C1-C 20 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C1-C 12 In an embodiment, R 1 is an unsubstituted unbranched unsaturated C1-C8 alkyl group. 1 is an unsubstituted unbranched unsaturated C1-C6 alkyl group. 1 is an unsubstituted unbranched unsaturated C1-C4 alkyl group. 1 It is an unsubstituted unbranched unsaturated C1-C2 alkyl group.

[0369] In an embodiment, R 1 is unsubstituted C9-C 19 In an embodiment, R 1 It is an unsubstituted branched C9-C 19 In an embodiment, R 1 It is an unsubstituted unbranched C9-C 19 In an embodiment, R 1 It is an unsubstituted branched saturated C9-C 19 In an embodiment, R1 It is an unsubstituted branched unsaturated C9-C 19 In an embodiment, R 1 It is an unsubstituted unbranched saturated C9-C 19 In an embodiment, R 1 It is an unsubstituted unbranched unsaturated C9-C 19 alkyl.

[0370] In an embodiment, R 2 is an unsubstituted alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 is an unsubstituted C1-C 25 In an embodiment, R 2 is an unsubstituted C1-C 20 In an embodiment, R 2 is an unsubstituted C1-C 12 In an embodiment, R 2 is an unsubstituted C1-C8 alkyl. 2 is an unsubstituted C1-C6 alkyl. 2 is an unsubstituted C1-C4 alkyl group. 2 It is an unsubstituted C1-C2 alkyl group.

[0371] In an embodiment, R 2 is an unsubstituted branched alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 It is an unsubstituted branched C1-C 25 In an embodiment, R 2 It is an unsubstituted branched C1-C 20 In an embodiment, R 2 It is an unsubstituted branched C1-C 12 In an embodiment, R 2 is an unsubstituted branched C1-C8 alkyl group. 2 is an unsubstituted branched C1-C6 alkyl group. 2 is an unsubstituted branched C1-C4 alkyl group. 2 It is an unsubstituted branched C1-C2 alkyl group.

[0372] In an embodiment, R2 is an unsubstituted unbranched alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 It is an unsubstituted unbranched C1-C 25 In an embodiment, R 2 It is an unsubstituted unbranched C1-C 20 In an embodiment, R 2 It is an unsubstituted unbranched C1-C 12 In an embodiment, R 2 is an unsubstituted unbranched C1-C8 alkyl group. 2 is an unsubstituted unbranched C1-C6 alkyl group. 2 is an unsubstituted unbranched C1-C4 alkyl group. 2 It is an unsubstituted unbranched C1-C2 alkyl group.

[0373] In an embodiment, R 2 is an unsubstituted branched saturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 It is an unsubstituted branched saturated C1-C 25 In an embodiment, R 2 It is an unsubstituted branched saturated C1-C 20 In an embodiment, R 2 It is an unsubstituted branched saturated C1-C 12 In an embodiment, R 2 is an unsubstituted branched saturated C1-C8 alkyl group. 2 is an unsubstituted branched saturated C1-C6 alkyl group. 2 is an unsubstituted branched saturated C1-C4 alkyl group. 2 It is an unsubstituted branched saturated C1-C2 alkyl group.

[0374] In an embodiment, R 2 is an unsubstituted branched unsaturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2It is an unsubstituted branched unsaturated C1-C 25 In an embodiment, R 2 It is an unsubstituted branched unsaturated C1-C 20 In an embodiment, R 2 It is an unsubstituted branched unsaturated C1-C 12 In an embodiment, R 2 is an unsubstituted branched unsaturated C1-C8 alkyl group. 2 is an unsubstituted branched unsaturated C1-C6 alkyl group. 2 is an unsubstituted branched unsaturated C1-C4 alkyl group. 2 It is an unsubstituted branched saturated C1-C2 alkyl group.

[0375] In an embodiment, R 2 is an unsubstituted unbranched saturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 It is an unsubstituted unbranched saturated C1-C 25 In an embodiment, R 2 It is an unsubstituted unbranched saturated C1-C 20 In an embodiment, R 2 It is an unsubstituted unbranched saturated C1-C 12 In an embodiment, R 2 is an unsubstituted, unbranched, saturated C1-C8 alkyl group. 2 is an unsubstituted, unbranched, saturated C1-C6 alkyl group. 2 is an unsubstituted, unbranched, saturated C1-C4 alkyl group. 2 It is an unsubstituted unbranched saturated C1-C2 alkyl group.

[0376] In an embodiment, R 2 is an unsubstituted unbranched unsaturated alkyl group (e.g., C1-C 25 、C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2). In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C1-C 25 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C1-C 20 In an embodiment, R 2It is an unsubstituted unbranched unsaturated C1-C 12 In an embodiment, R 2 is an unsubstituted unbranched unsaturated C1-C8 alkyl group. 2 is an unsubstituted unbranched unsaturated C1-C6 alkyl group. 2 is an unsubstituted unbranched unsaturated C1-C4 alkyl group. 2 It is an unsubstituted unbranched unsaturated C1-C2 alkyl group.

[0377] In an embodiment, R 2 is unsubstituted C9-C 19 In an embodiment, R 2 It is an unsubstituted branched C9-C 19 In an embodiment, R 2 It is an unsubstituted unbranched C9-C 19 In an embodiment, R 2 It is an unsubstituted branched saturated C9-C 19 In an embodiment, R 2 It is an unsubstituted branched unsaturated C9-C 19 In an embodiment, R 2 It is an unsubstituted unbranched saturated C9-C 19 In an embodiment, R 2 It is an unsubstituted unbranched unsaturated C9-C 19 alkyl.

[0378] In an embodiment, R 3 is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted alkyl (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heteroalkyl (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted cycloalkyl (e.g., C3-C 10, C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted heterocycloalkyl (e.g., 3 to 10-membered, 3 to 8-membered, 3 to 6-membered, 4 to 6-membered, 4 to 5-membered or 5 to 6-membered), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) or unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) or unsubstituted heteroaryl (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, R 3 is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) alkyl (e.g., C1-C 20 、C1-C 12 , C1-C8, C1-C6, C1-C4 or C1-C2), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heteroalkyl (e.g., 2 to 20 members, 2 to 12 members, 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members or 4 to 5 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) cycloalkyl (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) heterocycloalkyl (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), substituted (e.g., substituted by a substituent group, a size-restricted substituent group or a lower substituent group) aryl (e.g., C6-C 12 、C6-C 10 or phenyl) or substituted (e.g., substituted with a substituent group, a size-restricted substituent group, or a lower substituent group) heteroaryl (e.g., 5 to 12-membered, 5 to 10-membered, 5 to 9-membered, or 5 to 6-membered). In embodiments, R 3 is hydrogen, -NH2, -OH, -SH, -C(O)H, -C(O)NH2, -NHC(O)H, -NHC(O)OH, -NHC(O)NH2, -C(O)OH, -OC(O)H, -N3, unsubstituted alkyl (e.g., C1-C 20 、C1-C12 , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 20-membered, 2 to 12-membered, 2 to 8-membered, 2 to 6-membered, 4 to 6-membered, 2 to 3-membered or 4 to 5-membered), unsubstituted cycloalkyl (e.g., C3-C 10 , C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 10 members, 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members or 5 to 6 members), unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl) or unsubstituted heteroaryl (e.g., 5 to 12 members, 5 to 10 members, 5 to 9 members, or 5 to 6 members). In embodiments, when R 3 When replaced, R 3 In an embodiment, when R 3 When replaced, R 3 is substituted with a substituent group of limited size. In an embodiment, when R 3 When replaced, R 3 Substituted with a lower substituent group.

[0379] In embodiments, a lipid-modified nucleic acid compound comprises a motif as described herein, including any aspect, embodiment, claim, figure (e.g., Figure 1-83 ,in particular Figure 1-1 2 and Figures 80-83), Table (e.g., Table 1), Examples or Schemes (e.g., Schemes I, II, and III). In embodiments, the lipid-modified nucleic acid compound comprises a motif selected from any one of the motifs in Table 1 below. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-01 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-03 motif 1 in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-06 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-07 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-08 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-09 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-11 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-12 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-13 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-30 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-31 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-32 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-33 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-34 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-35 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-36 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-39 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-43 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-44 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-45 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-46 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-50 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-51 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-52 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-53 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-54 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-55 motif in Table 1.In embodiments, the lipid-modified nucleic acid compound comprises the DTx-03-06 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-03-50 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-03-51 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-03-52 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-03-53 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-03-54 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-03-55 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-04-01 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-05-01 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-06-06 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-06-50 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-06-51 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-06-52 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-06-53 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-06-54 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-06-55 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-08-01 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-09-01 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-10-01 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-11-01 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-60 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-61 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-62 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-63 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-64 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-65 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-66 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-67 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-68 motif in Table 1.In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-69 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-70 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-71 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-72 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-73 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-74 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-75 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-76 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-77 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-78 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-79 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-80 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-81 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-82 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-83 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-84 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-85 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-86 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-87 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-88 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-89 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-90 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-91 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-92 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-93 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-94 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-95 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-96 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-97 motif in Table 1.In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-98 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-99 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-100 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises the DTx-01-101 motif in Table 1.

[0380] In embodiments of compounds having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety of the compound at either of its 3' termini. In embodiments, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' terminus of its guide strand. In embodiments, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' terminus of its passenger strand.

[0381] In embodiments of compounds having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety of the compound at either of its 5' termini. In embodiments, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' terminus of its guide strand. In embodiments, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' terminus of its passenger strand.

[0382] In embodiments having a structure of Formula I, Ia, Ib, II, IIa, or IIb, conjugation to the 3' terminus is via a phosphodiester bond. In embodiments having a structure of Formula I, Ia, Ib, II, IIa, or IIb, conjugation to the 5' terminus is via a phosphodiester bond.

[0383] In embodiments of Formula III, IIIa, or IIIb, A is a modified double-stranded oligonucleotide, Z1 is conjugated to the 3' end of the passenger strand of the modified double-stranded oligonucleotide, and Z2 is conjugated to the 5' end of the passenger strand of the modified double-stranded oligonucleotide.

[0384] In embodiments of Formula III, IIIa, or IIIb, A is a modified double-stranded oligonucleotide, Z1 is conjugated to the 3' end of the guide strand of the modified double-stranded oligonucleotide, and Z2 is conjugated to the 5' end of the passenger strand of the modified double-stranded oligonucleotide.

[0385] In an embodiment, provided herein is a method for introducing a modified double-stranded oligonucleotide into a cell in vitro by contacting the cell with a lipid-conjugated compound of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa or IIIb, or its corresponding pharmaceutically acceptable salt, under free uptake conditions. In an embodiment, the compound is directly contacted with the cell. In an embodiment, the cell is a mammalian cell. In an embodiment, the cell is a human cell. In an embodiment, the cell is a mouse cell. In an embodiment, the cell is a fibroblast. In an embodiment, the cell is an NIH3T3 cell. In an embodiment, the cell is a kidney cell. In an embodiment, the cell is a HEK293 cell. In an embodiment, the cell is an endothelial cell. In an embodiment, the cell is a HUVEC cell. In an embodiment, the cell is an adipocyte. In an embodiment, the cell is a differentiated 3T3L1 cell. In an embodiment, the cell is a macrophage. In an embodiment, the cell is a RAW264.7 cell. In an embodiment, the cell is a neuronal cell. In an embodiment, the cell is a primary rat neuron. In an embodiment, the cell is an SH-SY5Y cell. In an embodiment, the cell is a muscle cell. In embodiments, the cell is a differentiated primary human skeletal muscle cell. In embodiments, the cell is a cell of the trabecular meshwork. In embodiments, the cell may be from an immortalized cell line. In embodiments, the cell may be from a primary cell. In embodiments, the cell is an adipocyte. In embodiments, the cell is a human adipocyte. In embodiments, the cell is a hepatocyte. In embodiments, the cell is a human hepatocyte. In embodiments, the cell is a T cell.

[0386] In embodiments, provided herein are methods for introducing a modified double-stranded oligonucleotide into a cell in vivo by intravitreal injection of a lipid-conjugated compound of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or its corresponding pharmaceutically acceptable salt. In embodiments, the cell is an ocular cell. In embodiments, the ocular cell is a photoreceptor cell, a bipolar cell, a ganglion cell, a horizontal cell, amacrine cell, a corneal epithelial cell, a corneal endothelial cell, or a corneal stromal cell. In embodiments, the corneal epithelial cell is a basal cell, a wing cell, or a squamous cell.

[0387] In the embodiments, provided herein are methods for introducing a modified double-stranded oligonucleotide into a cell in vivo by intrathecal administration. In the embodiments, provided herein are methods for introducing a modified double-stranded oligonucleotide into a cell by intraventricular administration.

[0388] In the embodiments, provided herein are methods for introducing modified double-stranded oligonucleotides into cells in vivo by contact systemic administration of a lipid-conjugated compound of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa or IIIb, or a corresponding pharmaceutically acceptable salt thereof.

[0389] In embodiments, provided herein are methods of introducing a lipid-conjugated compound of any of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or a pharmaceutically acceptable salt thereof, into a cell. In embodiments, the cell is in vitro. In embodiments, the cell is ex vivo. In embodiments, the cell is in vivo.

[0390] In an embodiment, provided herein is a method of administering a lipid-conjugated compound of any of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or a corresponding pharmaceutically acceptable salt thereof, to a subject. The subject may have a disease or disorder of the eye, brain, liver, kidney, heart, adipose tissue, lung, muscle, or spleen.

[0391] In embodiments, the disease or disorder of the eye is blepharitis, cataract, chalazion, conjunctivitis, diabetic retinopathy, dry eye, glaucoma, keratitis, keratoconus, macular degeneration, ocular allergy, intraocular hypertension, conjunctival maculopathy, presbyopia, pterygium, retinoblastoma, subconjunctival hemorrhage, or uveitis.

[0392] In embodiments, the disease or disorder is a neurological disease or disorder, a metabolic disease or disorder, an inflammatory disease or disorder.In embodiments, the subject has cancer.

[0393] In any embodiment related to in vivo administration or administration to a subject, administration is systemic administration, which may include but is not limited to subcutaneous administration, intravenous administration, intramuscular administration, and oral administration. In any embodiment related to in vivo administration or administration to a subject, administration is local administration, which may include but is not limited to intravitreal administration, intrathecal administration, and intraventricular administration.

[0394] In an embodiment, provided herein is a method for introducing a modified double-stranded oligonucleotide in vitro, comprising contacting a cell with a compound of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa or IIIb, or a corresponding pharmaceutically acceptable salt thereof, under free uptake conditions. In an embodiment, the cell is a neuron, a TBM cell, a skeletal muscle cell, an adipocyte, or a hepatocyte.

[0395] In embodiments, provided herein is a cell containing a compound having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or its corresponding pharmaceutically acceptable salt. In embodiments, the cell is a mammalian cell. In embodiments, the cell is a human cell. In embodiments, the cell is a mouse cell. In embodiments, the cell is a fibroblast. In embodiments, the cell is an NIH3T3 cell. In embodiments, the cell is a kidney cell. In embodiments, the cell is a HEK293 cell. In embodiments, the cell is an endothelial cell. In embodiments, the cell is a HUVEC cell. In embodiments, the cell is an adipocyte. In embodiments, the cell is a differentiated 3T3L1 cell. In embodiments, the cell is a macrophage. In embodiments, the cell is a RAW264.7 cell. In embodiments, the cell is a neuronal cell. In embodiments, the cell is a primary rat neuron. In embodiments, the cell is an SH-SY5Y cell. In embodiments, the cell is a muscle cell. In embodiments, the cell is a differentiated primary human skeletal muscle cell. In embodiments, the cell is a cell of the trabecular meshwork. In embodiments, the cells may be from an immortalized cell line. In embodiments, the cells may be from a primary cell. In embodiments, the cells are adipocytes. In embodiments, the cells are human adipocytes. In embodiments, the cells are hepatocytes. In embodiments, the cells are human hepatocytes. In embodiments, the cells are primary human adipocytes. In embodiments, the cells are primary HUVEC cells. In embodiments, the cells are primary human hepatocytes.

[0396] In embodiments, the cells contain a compound having the structure of Formula III:

[0397]

[0398] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to Z1 at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide, wherein Z1 is

[0399] and

[0400] wherein the modified double-stranded oligonucleotide is conjugated to Z2 at the 5' end of one strand of the modified double-stranded oligonucleotide or the 5' end of the modified single-stranded oligonucleotide, wherein Z2 is

[0401]

[0402] In embodiments, the cells contain a compound having the structure of Formula IIIa:

[0403]

[0404] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is bound to a lipid moiety at the 3' end of one chain of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide. Conjugated, and wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or the 5' end of the modified single-stranded oligonucleotide conjugation.

[0405] In embodiments, the cells contain a compound having the structure of Formula IIIb:

[0406]

[0407] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is bound to a lipid moiety at the 3' end of one chain of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide. Conjugated, and wherein the modified double-stranded oligonucleotide or single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or the 5' end of the modified single-stranded oligonucleotide conjugation.

[0408] In embodiments of cells containing a compound having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, the cell is a mammalian cell. In embodiments, the cell is a human cell. In embodiments, the cell is an endothelial cell. In embodiments, the cell is a HUVEC cell.

[0409] In embodiments of cells containing a compound having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety of the compound at either of its 3' termini. In embodiments, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' terminus of its guide strand. In embodiments, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' terminus of its passenger strand.

[0410] In embodiments of cells containing a compound having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, conjugation occurs through a phosphodiester bond.

[0411] In embodiments of cells containing a compound having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety of the compound at either of its 5' termini. In embodiments, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' terminus of its guide strand. In embodiments, the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' terminus of its passenger strand.

[0412] In embodiments of cells containing a compound having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, conjugation occurs through a phosphodiester bond.

[0413] In an embodiment, provided herein is a method for introducing a modified double-stranded oligonucleotide into human umbilical vein endothelial cells, NIH3T3 cells, RAW264.7 cells, HEK293 cells, or SH-SY5Y cells in vitro, comprising contacting the cells with a compound having a structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or a corresponding pharmaceutically acceptable salt thereof, under free uptake conditions. In an embodiment of the method, the compound can be:

[0414]

[0415] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to Z1 at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide, wherein Z1 is and wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to Z2 at the 5' end of one strand of the modified double-stranded oligonucleotide or the 5' end of the modified single-stranded oligonucleotide, wherein Z2 is

[0416] In an embodiment of the method, the compound may be:

[0417]

[0418] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is bound to a lipid moiety at the 3' end of one chain of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide. Conjugated, and wherein the modified double-stranded oligonucleotide or single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or the 5' end of the modified single-stranded oligonucleotide conjugation.

[0419] In an embodiment of the method, the compound may be:

[0420]

[0421] or a pharmaceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, wherein the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is bound to a lipid moiety at the 3' end of one chain of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide. Conjugated, and wherein the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or the 5' end of the modified single-stranded oligonucleotide conjugation.

[0422] In an embodiment of a method for introducing a modified double-stranded oligonucleotide into human umbilical vein endothelial cells, NIH3T3 cells, RAW264.7 cells, HEK293 cells, or SH-SY5Y cells in vitro, the method comprises contacting the cells with a compound having a structure of Formula III, IIIa, or IIIb under conditions of free uptake, wherein the modified double-stranded oligonucleotide is conjugated to a lipid-containing portion of the compound at either end of its 3' terminus. In an embodiment, the modified double-stranded oligonucleotide is conjugated to a lipid-containing portion at the 3' terminus of its guide strand. In an embodiment, the modified double-stranded oligonucleotide is conjugated to a lipid-containing portion at the 3' terminus of its passenger strand.

[0423] In an embodiment of a method for introducing a modified double-stranded oligonucleotide into human umbilical vein endothelial cells, NIH3T3 cells, RAW264.7 cells, HEK293 cells, or SH-SY5Y cells in vitro, the method comprises contacting the cells with a compound having the structure of Formula III, IIIa, or IIIb under free uptake conditions, and conjugation occurs through a phosphodiester bond.

[0424] In an embodiment of a method for introducing a modified double-stranded oligonucleotide into human umbilical vein endothelial cells, NIH3T3 cells, RAW264.7 cells, HEK293 cells, or SH-SY5Y cells in vitro, the method comprises contacting the cells with a compound having a structure of Formula III, IIIa, or IIIb under free uptake conditions, wherein the modified double-stranded oligonucleotide is conjugated to a lipid-containing portion of the compound at either end of its 5' terminus. In an embodiment, the modified double-stranded oligonucleotide is conjugated to a lipid-containing portion at the 5' terminus of its guide strand. In an embodiment, the modified double-stranded oligonucleotide is conjugated to a lipid-containing portion at the 5' terminus of its passenger strand.

[0425] In an embodiment of a method for introducing a modified double-stranded oligonucleotide into human umbilical vein endothelial cells, NIH3T3 cells, RAW264.7 cells, HEK293 cells, or SH-SY5Y cells in vitro, the method comprises contacting the cells with a compound having the structure of Formula III, IIIa, or IIIb under free uptake conditions, and conjugation occurs through a phosphodiester bond.

[0426] In embodiments, the modified double-stranded oligonucleotide is a small interfering RNA (siRNA).In embodiments, the modified double-stranded oligonucleotide is a microRNA mimic.

[0427] In an embodiment, the modified single-stranded oligonucleotide targets messenger RNA. In an embodiment, the modified single-stranded oligonucleotide is an RNase H oligonucleotide, which relies on RNase H to cleave its complementary mRNA. In an embodiment, the modified single-stranded oligonucleotide is a single-stranded siRNA. In an embodiment, the modified single-stranded oligonucleotide targets microRNA. In an embodiment, the modified single-stranded oligonucleotide targets long non-coding RNA.

[0428] In an embodiment, the modified double-stranded oligonucleotide contains at least one phosphorothioate bond. In some such embodiments, the modified double-stranded oligonucleotide contains two to thirteen phosphorothioate bonds. In some specific embodiments, the modified double-stranded oligonucleotide contains four phosphorothioate bonds. In some specific embodiments, the modified double-stranded oligonucleotide contains two phosphorothioate bonds at the 3' end of the guide strand and two phosphorothioate bonds at the 3' end of the passenger strand. In some specific embodiments, the modified double-stranded oligonucleotide contains two phosphorothioate bonds at the 5' end of the guide strand and two phosphorothioate bonds at the 3' end of the passenger strand. In some specific embodiments, the modified double-stranded oligonucleotide contains five phosphorothioate bonds. In some specific embodiments, the modified double-stranded oligonucleotide contains six phosphorothioate bonds. In some specific embodiments, the modified double-stranded oligonucleotide contains seven phosphorothioate bonds. In some specific embodiments, the modified double-stranded oligonucleotide contains eight phosphorothioate bonds. In some specific embodiments, the modified double-stranded oligonucleotide contains nine phosphorothioate bonds. In some specific embodiments, the modified double-stranded oligonucleotide contains ten phosphorothioate bonds. In some specific embodiments, the modified double-stranded oligonucleotide contains eleven phosphorothioate bonds. In some specific embodiments, the modified double-stranded oligonucleotide contains twelve phosphorothioate bonds. In some specific embodiments, the modified double-stranded oligonucleotide contains thirteen phosphorothioate bonds. In some specific embodiments, the modified double-stranded oligonucleotide contains two phosphorothioate bonds at the 3' end of the guide strand, seven phosphorothioate bonds at the 5' end of the guide strand, two phosphorothioate bonds at the 3' end of the passenger strand, and two phosphorothioate bonds at the 5' end of the passenger strand.

[0429] In embodiments, the modified double-stranded oligonucleotide contains at least one phosphoramidate bond. In embodiments, the modified double-stranded oligonucleotide contains at least one phosphorodithioate bond. In embodiments, the modified double-stranded oligonucleotide contains at least one boron phosphonate bond. In embodiments, the modified double-stranded oligonucleotide contains at least one O-methylphosphoramidite bond. In embodiments, the modified double-stranded oligonucleotide contains a normal backbone. In embodiments, the modified double-stranded oligonucleotide contains a non-ionic backbone.

[0430] In an embodiment, the modified double-stranded oligonucleotide contains at least one 2'-O-methyl residue. In an embodiment, at least one 2'-O-methyl residue is present on the guide strand, the passenger strand, or the guide strand and the passenger strand. In an embodiment, the modified double-stranded oligonucleotide contains at least one 2'-deoxy-2'-fluoro residue. In an embodiment, at least one 2'-deoxy-2'-fluoro residue is present on the guide strand, the passenger strand, or the guide strand and the passenger strand. In an embodiment, the modified double-stranded oligonucleotide contains 2'-O-methyl residues alternating with 2'-deoxy-2'-fluoro residues. In an embodiment, such alternating residues are present on the guide strand, the passenger strand, or the guide strand and the passenger strand. In an embodiment, the modified double-stranded oligonucleotide contains three 2'-O-methyl residues on the passenger strand and three 2'-deoxy-2'-fluoro residues on the guide strand. In an embodiment, each residue in the modified double-stranded oligonucleotide is a 2'-O-methyl residue or a 2'-deoxy-2'-fluoro residue. In an embodiment, the double-stranded oligonucleotide of modification contains at least one residue, wherein ribose is locked by the covalent bond between 2' carbon and 4' carbon, i.e., the residue is a bicyclic nucleic acid (BNA) residue. In an embodiment, bicyclic nucleic acid is a locked nucleic acid (LNA) residue. In an embodiment, bicyclic nucleic acid residue is a restricted ethyl (cEt) residue, also referred to as a cEt residue. In an embodiment, the double-stranded oligonucleotide of modification includes unlocked nucleic acid (UNA) residues. In an embodiment, the double-stranded oligonucleotide of modification contains a non-ribose backbone. In an embodiment, the double-stranded oligonucleotide of modification contains single-stranded locked nucleic acid (LNA), bicyclic nucleic acid (BNA), such as cEt, UNA or phosphorodiamidate morpholino oligomer (PMO), or its modification. In embodiments, the modified double-stranded oligonucleotide contains a single strand comprising at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, , 98% or 99% DNA, siRNA, mRNA, locked nucleic acid (LNA), bicyclic nucleic acid (BNA), such as cEt, UNA or phosphorodiamidate morpholino oligomer (PMO), or modifications thereof, etc., or the oligonucleotide may include a certain amount of DNA, siRNA, mRNA, locked nucleic acid (LNA), bicyclic nucleic acid (BNA), such as cEt, UNA or phosphorodiamidate morpholino oligomer (PMO), or modifications thereof, etc., and the amount is within the range defined by any two of the foregoing values.In embodiments, the modified double-stranded oligonucleotide contains a single strand comprising at least 1% and less than 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5% or 4% 2'-O-methoxyethyl / phosphorothioate (MOE).

[0431] In an embodiment, the modified double-stranded oligonucleotide comprises a 5'-(E)-vinylphosphonate group at the 5' end of the guide strand. In an embodiment, the modified double-stranded oligonucleotide is an siRNA comprising a 5'-(E)-vinylphosphonate group at the 5' end of the guide strand. In an embodiment, the modified double-stranded oligonucleotide is a microRNA mimic comprising a 5'-(E)-vinylphosphonate group at the 5' end of the guide strand. In an embodiment, the modified single-stranded oligonucleotide comprises a 5'-(E)-vinylphosphonate group at the 5' end of the oligonucleotide. In an embodiment, the modified single-stranded oligonucleotide is a single-stranded siRNA comprising a 5'-(E)-vinylphosphonate group at the 5' end of the guide strand.

[0432] The single-stranded oligonucleotide of any modification disclosed herein can include one or more nucleoside sugar modifications selected from 2'-O-methoxyethyl residues, dicyclic nucleic acid residues, 2'-O-methyl residues and 2'-fluoro residues. In an embodiment, the dicyclic nucleic acid residues are locked nucleic acid residues. In an embodiment, the dicyclic nucleic acid residues are cEt residues. The single-stranded nucleic acid (e.g., oligonucleotide) of any modification disclosed herein can include one or more phosphorothioate bonds. In an embodiment, each bond of the single-stranded oligonucleotide of modification is a phosphorothioate bond.

[0433] In embodiments, the double-stranded oligonucleotide is a small interfering RNA (siRNA).In embodiments, the double-stranded oligonucleotide is a microRNA mimic.

[0434] In an embodiment, the single stranded oligonucleotide targets a messenger RNA. In an embodiment, the single stranded oligonucleotide is an RNase H oligonucleotide, which relies on RNase H to cleave its complementary mRNA. In an embodiment, the single stranded oligonucleotide is a single stranded siRNA. In an embodiment, the single stranded oligonucleotide targets a microRNA. In an embodiment, the single stranded oligonucleotide targets a long non-coding RNA.

[0435] In embodiments, a double-stranded oligonucleotide contains at least one phosphorothioate bond. In some such embodiments, the double-stranded oligonucleotide contains two to thirteen phosphorothioate bonds. In some specific embodiments, the double-stranded oligonucleotide contains four phosphorothioate bonds. In some specific embodiments, the double-stranded oligonucleotide contains two phosphorothioate bonds at the 3' end of the guide strand and two phosphorothioate bonds at the 3' end of the passenger strand. In some specific embodiments, the double-stranded oligonucleotide contains two phosphorothioate bonds at the 5' end of the guide strand and two phosphorothioate bonds at the 3' end of the passenger strand. In some specific embodiments, the double-stranded oligonucleotide contains five phosphorothioate bonds. In some specific embodiments, the double-stranded oligonucleotide contains six phosphorothioate bonds. In some specific embodiments, the double-stranded oligonucleotide contains seven phosphorothioate bonds. In some specific embodiments, the double-stranded oligonucleotide contains eight phosphorothioate bonds. In some specific embodiments, the double-stranded oligonucleotide contains nine phosphorothioate bonds. In some specific embodiments, the double-stranded oligonucleotide contains ten phosphorothioate bonds. In some specific embodiments, the double-stranded oligonucleotide contains eleven phosphorothioate bonds. In some specific embodiments, the double-stranded oligonucleotide contains twelve phosphorothioate bonds. In some specific embodiments, the double-stranded oligonucleotide contains thirteen phosphorothioate bonds. In some specific embodiments, the double-stranded oligonucleotide contains two phosphorothioate bonds at the 3' end of the guide strand, seven phosphorothioate bonds at the 5' end of the guide strand, two phosphorothioate bonds at the 3' end of the...

Claims

1. A compound having the structure: in A is an oligonucleotide; L 3 independently -OPO2-O-; L 4 Independently L 5 For -L 5A -L 5B -L 5C -L 5D -L 5E -; Where L 5A is an unsubstituted C1-C8 alkylene group; L 5B L is independently a bond or unsubstituted phenylene; 5C L is independently a bond, an unsubstituted C2-C8 alkynylene group or an unsubstituted phenylene group; 5D are independently a bond or an unsubstituted C1-C8 alkylene group; and L 5E is -NHC(O)-; L 6 is -NHC(O)-; R 1 and R 2 are independently unsubstituted C1-C 25 Alkyl, where R 1 and R 2 At least one of them is unsubstituted C9-C 19 alkyl; R 3 is hydrogen; and t is an integer from 1 to 5.

2. The compound according to claim 1, wherein: (i) t is 1; or (ii) t is 2; or (iii) t is 3.

3. The compound according to claim 1, wherein A is a double-stranded oligonucleotide or a single-stranded oligonucleotide; Optionally, wherein the oligonucleotide of A is modified, Further optionally, wherein: (i) One L 3 is attached to the 3' carbon of the double-stranded oligonucleotide or single-stranded oligonucleotide; and / or (ii) One L 3 is attached to the 5' carbon of the double-stranded oligonucleotide or single-stranded oligonucleotide; and / or (iii) One L 3 is linked to the nucleobase of the double-stranded oligonucleotide or single-stranded oligonucleotide.

4. The compound according to any one of claims 1 to 3, wherein -L 3 -L 4 -for: and is attached to the 3' carbon of the double-stranded oligonucleotide or single-stranded oligonucleotide; or and is linked to the 5' carbon of the double-stranded oligonucleotide or the single-stranded oligonucleotide.

5. The compound according to any one of claims 1 to 3, wherein L 5 Independently 6. The compound according to any one of claims 1 to 3, wherein R 1 is unsubstituted C 13 -C 17 alkyl.

7. The compound according to any one of claims 1 to 3, wherein R 1 is an unsubstituted unbranched C 13 -C 17 alkyl.

8. A compound according to any one of claims 1 to 3, wherein R 1 is an unsubstituted unbranched saturated C 13 -C 17 alkyl.

9. The compound according to any one of claims 1 to 3, wherein R 1 is unsubstituted C 15 alkyl.

10. The compound according to any one of claims 1 to 3, wherein R 1 is an unsubstituted unbranched C 15 alkyl.

11. The compound according to any one of claims 1 to 3, wherein R 1 is an unsubstituted unbranched saturated C 15 alkyl.

12. The compound according to any one of claims 1 to 3, wherein R 2 is unsubstituted C 13 -C 17 alkyl.

13. A compound according to any one of claims 1 to 3, wherein R 2 is an unsubstituted unbranched C 13 -C 17 alkyl.

14. A compound according to any one of claims 1 to 3, wherein R 2 is an unsubstituted unbranched saturated C 13 -C 17 alkyl.

15. A compound according to any one of claims 1 to 3, wherein R 2 is unsubstituted C 15 alkyl.

16. A compound according to any one of claims 1 to 3, wherein R 2 is an unsubstituted unbranched C 15 alkyl.

17. A compound according to any one of claims 1 to 3, wherein R 2 is an unsubstituted unbranched saturated C 15 alkyl.

18. A compound according to any one of claims 1-3, wherein the oligonucleotide is a siRNA, a microRNA mimic, a stem-loop structure, a single-stranded siRNA, an RNase H oligonucleotide, an anti-microRNA oligonucleotide, a steric blocking oligonucleotide, a CRISPR guide RNA or an aptamer, optionally wherein the oligonucleotide is modified.

19. The compound of any one of claims 1-3, wherein the oligonucleotide comprises locked nucleic acid (LNA) residues, bicyclic nucleic acid (BNA) residues, constrained ethyl (cEt) residues, unlocked nucleic acid (UNA) residues, phosphorodiamidate morpholino oligomer (PMO) monomers, peptide nucleic acid (PNA) monomers, 2'-O-methyl (2'-OMe) residues, 2'-O-methyloxyethyl residues, 2'-deoxy-2'-fluoro residues, 2'-O-methoxyethyl / phosphorothioate residues, phosphoramidates, phosphorodiamidates, phosphorothioates, phosphorodithioates, phosphonocarboxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methylphosphonates, borophosphonates, or O-methylphosphoramidates.

20. A cell containing a compound according to any one of claims 1 to 19, Optionally, wherein the cell is (i) primary cells, Optionally, wherein the cell is an adipocyte, a hepatocyte, a fibroblast, an endothelial cell, a kidney cell, a macrophage, a neuronal cell or a muscle cell; or (ii) immortalized cells, Optionally, wherein the cell is a NIH3T3 cell, a differentiated 3T3L1 cell, a RAW264.7 cell or a SH-SY5Y cell.

21. A method for introducing an oligonucleotide into a cell in vitro, comprising contacting the cell with a compound according to any one of claims 1 to 19 under free uptake conditions, Optionally, wherein the cell is: (i) primary cells, Optionally, wherein the cell is an adipocyte, a hepatocyte, a fibroblast, an endothelial cell, a kidney cell, a macrophage, a neuronal cell, a rat neuron or a muscle cell; or (ii) immortalized cells, Optionally, wherein the cell is a NIH3T3 cell, a differentiated 3T3L1 cell, a RAW264.7 cell or a SH-SY5Y cell.

22. The cell of claim 20 or the method of claim 21, wherein the endothelial cells are human umbilical vein endothelial cells (HUVEC).

23. The cell of claim 20 or the method of claim 21, wherein the muscle cell is a differentiated primary human skeletal muscle cell.

24. A method for introducing an oligonucleotide into a cell in vitro, comprising: Obtain cells; and contacting the cell with a compound according to any one of claims 1 to 19 under free uptake conditions, Optionally, wherein the cell is a neuron, a TBM cell, a skeletal muscle cell, an adipocyte or a hepatocyte, or wherein the cell is a human umbilical vein endothelial cell.

25. A method comprising contacting a cell with a compound according to any one of claims 1-19, wherein the contacting occurs in vitro or ex vivo.

26. Use of a compound according to any one of claims 1 to 19 in the preparation of a medicament.

27. Use of a compound according to any one of claims 1 to 19 in the preparation of a medicament for treating a disease or condition in a subject, Optionally, wherein the subject suffers from a disease or disorder of the eye, liver, kidney, heart, adipose tissue, lung, muscle or spleen.

28. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound according to any one of claims 1-19.

Citation Information

Patent Citations

  • Uncharged morpholino-based polymers having achiral intersubunit linkages

    US5034506A

  • Alpha-morpholino ribonucleoside derivatives and polymers thereof

    US5235033A

  • Massive parallel method for decoding DNA and RNA

    US6664079B2

  • Cephalosporin derivatives

    WO1987005297A1

  • Targeting lipids

    CN102006890A